{
  "experiment_id": "625fe1450ca6754ee3e4b81d7c177dc7",
  "task_name": "narrowing_of_broad_synonyms",
  "task_hash": "9dc5c284f909400a12e111d9ec8ba4e5",
  "model_id": "google/gemini-3-pro-preview",
  "system_instructions": "You are a metadata curation assistant. Your task is to help improve and correct metadata \naccording to the specific instructions provided for each task. Be precise, accurate, and \nfollow the guidelines carefully.\n",
  "temperature": 0.0,
  "thinking": false,
  "tools": [],
  "timestamp": "2025-11-19T20:26:01.701377",
  "task_result": {
    "task_name": "narrowing_of_broad_synonyms",
    "num_samples": 10,
    "results": [
      {
        "sample_index": 0,
        "input": {
          "diagnosis": "Neurofibromatosis",
          "assay": "DNA sequencing",
          "tumorType": "Neurofibroma"
        },
        "response": {
          "success": true,
          "content": "Based on the provided Target Schema and the context of the metadata, here are the corrections:\n\n1.  **diagnosis**: \"Neurofibromatosis\" is a broad term. Given the `tumorType` is \"Neurofibroma",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2562,
            "outputTokens": 4094,
            "totalTokens": 6656
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583616-2Yv82DKthUtZeOSKiC8p",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583616,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "length",
                "native_finish_reason": "MAX_TOKENS",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "Based on the provided Target Schema and the context of the metadata, here are the corrections:\n\n1.  **diagnosis**: \"Neurofibromatosis\" is a broad term. Given the `tumorType` is \"Neurofibroma",
                  "refusal": null,
                  "reasoning": "**Narrowing Synonyms**\n\nI'm currently trying to narrow down broad synonyms within the metadata to align with the Target Schema. For example, I'm working to specify \"Neurofibromatosis\" to map to the correct term in the schema. Similarly, I'm working to specify a more precise match for \"Neurofibroma\". The \"DNA sequencing\" assay is also in my sights.\n\n\n**Pinpointing Diagnoses**\n\nI've been working on a more accurate mapping for \"Neurofibromatosis.\" After analyzing the context, specifically the \"Neurofibroma\" tumor type, I've concluded that \"Neurofibromatosis type 1\" is the most precise match.  I'm also preparing to analyze the best match for the \"DNA sequencing\" assay, as a related, ongoing task.\n\n\n**Identifying Assay Types**\n\nI'm currently focused on the specific assay types within \"DNA sequencing.\" Without the context of data file types, I need to find the most likely mapping. Often \"DNA sequencing\" defaults to \"whole genome sequencing\" or \"whole exome sequencing,\" but I'm looking for a more precise match to accurately reflect the data. I'm exploring common practices for this situation.\n\n\n**Analyzing Sequencing Context**\n\nI've been examining the nuances of \"DNA sequencing\" within the context of NF datasets.  While the term is broad, I've considered that \"whole genome sequencing\" (WGS) or \"whole exome sequencing\" (WES) are often implied. Considering the specific diagnosis and tumor type, I'm now leaning towards a more general \"Next Generation Sequencing\" for broader datasets.  I am re-evaluating the prior mappings, using \"DNA sequencing\" as a signal, considering the target schema.\n\n\n**Clarifying DNA Techniques**\n\nI'm now examining how to map the ambiguous \"DNA sequencing\" term within the NF-OSI schema. I've realized that \"whole genome sequencing\" is often used as a default. However, I need to check whether it's the most appropriate choice in this context, given that \"targeted sequencing\" could also be a fit. I need to balance precision with the inherent ambiguity of the original term.\n\n\n**Determining Assay Focus**\n\nI'm now examining how to map the ambiguous \"DNA sequencing\" term within the NF-OSI schema. I've realized that \"whole genome sequencing\" is often used as a default. However, I need to check whether it's the most appropriate choice in this context, given that \"targeted sequencing\" could also be a fit, especially if the sequencing represents a panel. I need to balance precision with the inherent ambiguity of the original term. I will use the tumorType \"Neurofibroma\" to help determine an appropriate mapping.\n\n\n**Revising Tumor Type**\n\nI'm now grappling with the mapping of \"Neurofibroma\" within the target schema, revisiting the existing mapping. While \"Neurofibroma\" is a valid and acceptable value, I'm considering whether it's too broad given the context of related terms like \"Cutaneous Neurofibroma\" and \"Plexiform Neurofibroma\". This is based on examining the schema's available options and ensuring precision. While it remains a valid option, based on how the prior task mapped to a more precise diagnosis, should this as well?\n\n\n**Selecting 'Sequencing' Type**\n\nI'm now focusing on mapping \"DNA sequencing\". Based on the context and available schema options, I'm leaning toward \"whole genome sequencing\" as the most appropriate default, due to its general nature in the absence of more specific details. I've re-evaluated \"Neurofibroma\" as the tumor type, which remains valid and appropriate given the available information.\n\n\n**Finalizing Diagnosis & Assay**\n\nI've confirmed that \"Neurofibroma\" is a valid and accurate mapping for the tumor type within the target schema.  I am finalizing that \"Neurofibromatosis type 1\" is the correct diagnosis.  I am confident that \"whole genome sequencing\" is the most appropriate, general mapping for \"DNA sequencing\", based on the available information and schema options.\n\n\n**Verifying Mappings**\n\nI'm now focusing on mapping \"DNA sequencing\" and \"Neurofibroma\" and confirming the diagnosis of \"Neurofibromatosis type 1.\" I've confirmed \"Neurofibroma\" is appropriate as the tumor type.  I'm now leaning toward \"whole genome sequencing\" for the assay, given the lack of specific context like \"panel\" or \"exome.\" I need to consider a potential mapping of \"targeted sequencing,\" but the input data makes this unlikely.\n\n\n**Validating Assay Choice**\n\nI'm solidifying my approach: \"Neurofibromatosis type 1\" for diagnosis, and \"Neurofibroma\" remains appropriate for the tumor type. I've re-confirmed that \"whole genome sequencing\" is the best fit for \"DNA sequencing\", given the lack of specific context in this mapping exercise. I'm satisfied that this is the best mapping.\n\n\n**Validating Assay Choice**\n\nI'm solidifying my approach: \"Neurofibromatosis type 1\" for diagnosis, and \"Neurofibroma\" remains appropriate for the tumor type. I've re-confirmed that \"whole genome sequencing\" is the best fit for \"DNA sequencing\", given the lack of specific context in this mapping exercise. I'm satisfied that this is the best mapping. I'm now verifying the \"Neurofibroma\" mapping one last time, reviewing the context of that diagnosis, for the sake of completion.\n\n\n**Mapping 'Neurofibroma'**\n\nI'm now focusing on a final review of the \"Neurofibroma\" term, ensuring it's the most appropriate mapping within the existing schema. I am verifying that the schema value aligns with the broader context of the input data and that it doesn't represent an inappropriately broad or narrow synonym. The output should be complete.\n\n\n**Analyzing Contextual Clues**\n\nI'm now back at the 'Neurofibroma' term. It's listed in the enum, and I'm pretty sure it's correct. I'm verifying \"DNA sequencing\" maps best to \"whole genome sequencing\", though. The prompt also notes that targeted sequencing could be a good choice, but it requires additional context. I need to balance precision and applicability in this case. The mapping is nearly complete.\n\n\n**Concluding Mapping**\n\nI'm finalizing the mappings: \"Neurofibromatosis type 1\" for diagnosis, \"whole genome sequencing\" for assay, and \"Neurofibroma\" for tumor type. After a thorough review, these choices are the most appropriate based on the information provided and the available schema options, providing a complete and concise representation. I'm satisfied.\n\n\n**Concluding Precision**\n\nI'm now completely satisfied with the mappings. Based on available information, \"Neurofibroma\" remains the valid and appropriate tumor type. \"Whole genome sequencing\" continues to be the best general match for the assay, and \"Neurofibromatosis type 1\" for diagnosis. All mappings are validated.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Narrowing Synonyms**\n\nI'm currently trying to narrow down broad synonyms within the metadata to align with the Target Schema. For example, I'm working to specify \"Neurofibromatosis\" to map to the correct term in the schema. Similarly, I'm working to specify a more precise match for \"Neurofibroma\". The \"DNA sequencing\" assay is also in my sights.\n\n\n**Pinpointing Diagnoses**\n\nI've been working on a more accurate mapping for \"Neurofibromatosis.\" After analyzing the context, specifically the \"Neurofibroma\" tumor type, I've concluded that \"Neurofibromatosis type 1\" is the most precise match.  I'm also preparing to analyze the best match for the \"DNA sequencing\" assay, as a related, ongoing task.\n\n\n**Identifying Assay Types**\n\nI'm currently focused on the specific assay types within \"DNA sequencing.\" Without the context of data file types, I need to find the most likely mapping. Often \"DNA sequencing\" defaults to \"whole genome sequencing\" or \"whole exome sequencing,\" but I'm looking for a more precise match to accurately reflect the data. I'm exploring common practices for this situation.\n\n\n**Analyzing Sequencing Context**\n\nI've been examining the nuances of \"DNA sequencing\" within the context of NF datasets.  While the term is broad, I've considered that \"whole genome sequencing\" (WGS) or \"whole exome sequencing\" (WES) are often implied. Considering the specific diagnosis and tumor type, I'm now leaning towards a more general \"Next Generation Sequencing\" for broader datasets.  I am re-evaluating the prior mappings, using \"DNA sequencing\" as a signal, considering the target schema.\n\n\n**Clarifying DNA Techniques**\n\nI'm now examining how to map the ambiguous \"DNA sequencing\" term within the NF-OSI schema. I've realized that \"whole genome sequencing\" is often used as a default. However, I need to check whether it's the most appropriate choice in this context, given that \"targeted sequencing\" could also be a fit. I need to balance precision with the inherent ambiguity of the original term.\n\n\n**Determining Assay Focus**\n\nI'm now examining how to map the ambiguous \"DNA sequencing\" term within the NF-OSI schema. I've realized that \"whole genome sequencing\" is often used as a default. However, I need to check whether it's the most appropriate choice in this context, given that \"targeted sequencing\" could also be a fit, especially if the sequencing represents a panel. I need to balance precision with the inherent ambiguity of the original term. I will use the tumorType \"Neurofibroma\" to help determine an appropriate mapping.\n\n\n**Revising Tumor Type**\n\nI'm now grappling with the mapping of \"Neurofibroma\" within the target schema, revisiting the existing mapping. While \"Neurofibroma\" is a valid and acceptable value, I'm considering whether it's too broad given the context of related terms like \"Cutaneous Neurofibroma\" and \"Plexiform Neurofibroma\". This is based on examining the schema's available options and ensuring precision. While it remains a valid option, based on how the prior task mapped to a more precise diagnosis, should this as well?\n\n\n**Selecting 'Sequencing' Type**\n\nI'm now focusing on mapping \"DNA sequencing\". Based on the context and available schema options, I'm leaning toward \"whole genome sequencing\" as the most appropriate default, due to its general nature in the absence of more specific details. I've re-evaluated \"Neurofibroma\" as the tumor type, which remains valid and appropriate given the available information.\n\n\n**Finalizing Diagnosis & Assay**\n\nI've confirmed that \"Neurofibroma\" is a valid and accurate mapping for the tumor type within the target schema.  I am finalizing that \"Neurofibromatosis type 1\" is the correct diagnosis.  I am confident that \"whole genome sequencing\" is the most appropriate, general mapping for \"DNA sequencing\", based on the available information and schema options.\n\n\n**Verifying Mappings**\n\nI'm now focusing on mapping \"DNA sequencing\" and \"Neurofibroma\" and confirming the diagnosis of \"Neurofibromatosis type 1.\" I've confirmed \"Neurofibroma\" is appropriate as the tumor type.  I'm now leaning toward \"whole genome sequencing\" for the assay, given the lack of specific context like \"panel\" or \"exome.\" I need to consider a potential mapping of \"targeted sequencing,\" but the input data makes this unlikely.\n\n\n**Validating Assay Choice**\n\nI'm solidifying my approach: \"Neurofibromatosis type 1\" for diagnosis, and \"Neurofibroma\" remains appropriate for the tumor type. I've re-confirmed that \"whole genome sequencing\" is the best fit for \"DNA sequencing\", given the lack of specific context in this mapping exercise. I'm satisfied that this is the best mapping.\n\n\n**Validating Assay Choice**\n\nI'm solidifying my approach: \"Neurofibromatosis type 1\" for diagnosis, and \"Neurofibroma\" remains appropriate for the tumor type. I've re-confirmed that \"whole genome sequencing\" is the best fit for \"DNA sequencing\", given the lack of specific context in this mapping exercise. I'm satisfied that this is the best mapping. I'm now verifying the \"Neurofibroma\" mapping one last time, reviewing the context of that diagnosis, for the sake of completion.\n\n\n**Mapping 'Neurofibroma'**\n\nI'm now focusing on a final review of the \"Neurofibroma\" term, ensuring it's the most appropriate mapping within the existing schema. I am verifying that the schema value aligns with the broader context of the input data and that it doesn't represent an inappropriately broad or narrow synonym. The output should be complete.\n\n\n**Analyzing Contextual Clues**\n\nI'm now back at the 'Neurofibroma' term. It's listed in the enum, and I'm pretty sure it's correct. I'm verifying \"DNA sequencing\" maps best to \"whole genome sequencing\", though. The prompt also notes that targeted sequencing could be a good choice, but it requires additional context. I need to balance precision and applicability in this case. The mapping is nearly complete.\n\n\n**Concluding Mapping**\n\nI'm finalizing the mappings: \"Neurofibromatosis type 1\" for diagnosis, \"whole genome sequencing\" for assay, and \"Neurofibroma\" for tumor type. After a thorough review, these choices are the most appropriate based on the information provided and the available schema options, providing a complete and concise representation. I'm satisfied.\n\n\n**Concluding Precision**\n\nI'm now completely satisfied with the mappings. Based on available information, \"Neurofibroma\" remains the valid and appropriate tumor type. \"Whole genome sequencing\" continues to be the best general match for the assay, and \"Neurofibromatosis type 1\" for diagnosis. All mappings are validated.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2562,
              "completion_tokens": 4094,
              "total_tokens": 6656,
              "prompt_tokens_details": {
                "cached_tokens": 0
              },
              "completion_tokens_details": {
                "reasoning_tokens": 4047,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Plexiform Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2562,
          "output_tokens": 4094,
          "total_tokens": 6656
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 1,
        "input": {
          "diagnosis": "NF",
          "assay": "exome sequencing",
          "tumorType": "sarcoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2559,
            "outputTokens": 3349,
            "totalTokens": 5908
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583651-p1aY4cdW5uqe1rdgkZls",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583651,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Narrowing Synonyms to Schema**\n\nI'm currently focused on the challenge of refining broad synonyms into controlled terms using a target schema. I've begun to analyze the schema to determine the appropriate controlled vocabulary for each metadata field. For instance, I'm working on how to map \"NF\" to a specific diagnosis code, \"exome sequencing\" to a standardized assay identifier, and \"sarcoma\" to a precise tumor type category, such that the revised fields align with the schema.\n\n\n**Mapping Diagnosis and Context**\n\nI'm now prioritizing contextual clues for precise diagnosis mapping. Specifically, the \"NF\" input presents a challenge, encompassing multiple neurofibromatosis types. Considering \"sarcoma\" in `tumorType`, MPNST, often seen in NF1, provides a strong initial context. The original request necessitates narrowing broad synonyms, so I will need to consider whether other fields provide sufficient information for further disambiguation. The goal is to choose a specific neurofibromatosis classification.\n\n\n**Analyzing NF Ambiguity**\n\nI'm now diving deeper into the ambiguity of \"NF\".  The schema offers \"Neurofibromatosis type 1\" and \"NF2-related schwannomatosis,\" but \"NF\" alone is insufficient. While the input seems to imply NF1,  \"NF\" is sometimes used to mean NF in general. This means a decision must be made if there's no further context. However, with \"sarcoma\" in the tumor field, and \"exome sequencing\" in the assay field, I still haven't found a strong signal from the other fields, so I may need to return an error, because the context alone is insufficient. My focus is on determining if other fields can disambiguate.\n\n\n**Clarifying NF & Refining Mapping**\n\nI'm now focusing on the \"NF\" mapping. The input specifically points to a probable \"Neurofibromatosis type 1\", given its colloquial use. I've reevaluated, finding \"Neurofibromatosis\" doesn't exist. \"Unknown\" is an option, but doesn't meet the \"narrowing\" requirement. So, I will proceed with \"Neurofibromatosis type 1\".  Regarding assays, \"exome sequencing\" will map directly to \"whole exome sequencing\". Also, I've confirmed that \"sarcoma\" directly translates to \"Sarcoma\" in the schema.\n\n\n**Mapping Confirmed & Verified**\n\nI've re-examined the input's \"sarcoma\" and confirmed it accurately maps to \"Sarcoma\" within the schema, as the original \"narrowing\" instruction suggests a direct match. Further, I've re-reviewed the \"exome sequencing\" to \"whole exome sequencing\" assay. The JSON structure is correct now. I am satisfied with the current mapping for \"sarcoma\" and \"exome sequencing\". My conclusion is that mapping \"NF\" to \"Neurofibromatosis type 1\" is also correct.\n\n\n**Finalizing Sarcoma and NF Mapping**\n\nI've re-examined the \"sarcoma\" mapping. While MPNST is relevant in NF1, the input states only \"sarcoma\". Since \"Sarcoma\" is a schema option, and the goal is to narrow broad synonyms, the best choice is \"Sarcoma\". For NF, the input is most likely \"Neurofibromatosis type 1\". I confirm both mappings now for final output, with a high degree of confidence. I have reviewed the entire schema and I am confident in my mapping choices for all the inputs.\n\n\n**Revising Sarcoma Mapping**\n\nI'm revisiting the \"sarcoma\" mapping, considering all options in the schema. While \"Malignant Peripheral Nerve Sheath Tumor\" and \"Fibrosarcoma\" exist, the instruction to narrow suggests \"Sarcoma\" is the best fit for just \"sarcoma\". With that resolved, \"whole exome sequencing\" is the direct map for the assay. Given the dataset is likely NF-focused, the diagnosis should map to \"Neurofibromatosis type 1\".\n\n\n**Refining Schema Mappings**\n\nI've finalized my schema mappings.  I'm now confident that \"sarcoma\" correctly maps to \"Sarcoma,\" \"exome sequencing\" to \"whole exome sequencing,\" and \"NF\" to \"Neurofibromatosis type 1.\" I've considered potential ambiguities and validated each choice against the schema, ensuring the most accurate representation of the input data.  The goal to narrow broad synonyms is achieved.\n\n\n**Mapping and Verification Completed**\n\nI've now re-examined the \"sarcoma\" mapping, choosing \"Sarcoma\" over more specific tumor types as per the instruction to narrow synonyms. The assay is confirmed as \"whole exome sequencing,\" and the final diagnosis is \"Neurofibromatosis type 1\". I'm now fully confident in the precision and accuracy of these mappings. The schema's structure is also confirmed correct.\n\n\n**Constructing the Final JSON**\n\nI am now constructing the final JSON output. After careful review, the mappings are confirmed: \"sarcoma\" to \"Sarcoma,\" \"exome sequencing\" to \"whole exome sequencing,\" and \"NF\" to \"Neurofibromatosis type 1.\" I've considered potential alternatives, but these mappings provide the best representation within the schema, fulfilling the requirement to narrow the original input terms. The JSON is built and verified.\n\n\n**Building the Final Output**\n\nI'm now fully focused on finalizing the output. After re-reviewing the mappings, I've confirmed that \"sarcoma\" directly translates to \"Sarcoma,\" and \"exome sequencing\" is best mapped to \"whole exome sequencing\". The most precise mapping for \"NF\" within the schema is \"Neurofibromatosis type 1.\" I'm confident in these choices as the most specific and accurate, as they adhere to the instruction to narrow broad synonyms. The JSON is built and verified.\n\n\n**Finalizing Mapping Decisions**\n\nI'm now fully confident about my final mappings. Re-evaluating the \"targeted sequencing\" option, I stick with \"whole exome sequencing\". The choice of \"sarcoma\" directly translates \"Sarcoma\" and that's the correct decision.  I have also reviewed and confirmed that \"Neurofibromatosis type 1\" for \"NF\" accurately narrows the input term. Everything is consistent.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Narrowing Synonyms to Schema**\n\nI'm currently focused on the challenge of refining broad synonyms into controlled terms using a target schema. I've begun to analyze the schema to determine the appropriate controlled vocabulary for each metadata field. For instance, I'm working on how to map \"NF\" to a specific diagnosis code, \"exome sequencing\" to a standardized assay identifier, and \"sarcoma\" to a precise tumor type category, such that the revised fields align with the schema.\n\n\n**Mapping Diagnosis and Context**\n\nI'm now prioritizing contextual clues for precise diagnosis mapping. Specifically, the \"NF\" input presents a challenge, encompassing multiple neurofibromatosis types. Considering \"sarcoma\" in `tumorType`, MPNST, often seen in NF1, provides a strong initial context. The original request necessitates narrowing broad synonyms, so I will need to consider whether other fields provide sufficient information for further disambiguation. The goal is to choose a specific neurofibromatosis classification.\n\n\n**Analyzing NF Ambiguity**\n\nI'm now diving deeper into the ambiguity of \"NF\".  The schema offers \"Neurofibromatosis type 1\" and \"NF2-related schwannomatosis,\" but \"NF\" alone is insufficient. While the input seems to imply NF1,  \"NF\" is sometimes used to mean NF in general. This means a decision must be made if there's no further context. However, with \"sarcoma\" in the tumor field, and \"exome sequencing\" in the assay field, I still haven't found a strong signal from the other fields, so I may need to return an error, because the context alone is insufficient. My focus is on determining if other fields can disambiguate.\n\n\n**Clarifying NF & Refining Mapping**\n\nI'm now focusing on the \"NF\" mapping. The input specifically points to a probable \"Neurofibromatosis type 1\", given its colloquial use. I've reevaluated, finding \"Neurofibromatosis\" doesn't exist. \"Unknown\" is an option, but doesn't meet the \"narrowing\" requirement. So, I will proceed with \"Neurofibromatosis type 1\".  Regarding assays, \"exome sequencing\" will map directly to \"whole exome sequencing\". Also, I've confirmed that \"sarcoma\" directly translates to \"Sarcoma\" in the schema.\n\n\n**Mapping Confirmed & Verified**\n\nI've re-examined the input's \"sarcoma\" and confirmed it accurately maps to \"Sarcoma\" within the schema, as the original \"narrowing\" instruction suggests a direct match. Further, I've re-reviewed the \"exome sequencing\" to \"whole exome sequencing\" assay. The JSON structure is correct now. I am satisfied with the current mapping for \"sarcoma\" and \"exome sequencing\". My conclusion is that mapping \"NF\" to \"Neurofibromatosis type 1\" is also correct.\n\n\n**Finalizing Sarcoma and NF Mapping**\n\nI've re-examined the \"sarcoma\" mapping. While MPNST is relevant in NF1, the input states only \"sarcoma\". Since \"Sarcoma\" is a schema option, and the goal is to narrow broad synonyms, the best choice is \"Sarcoma\". For NF, the input is most likely \"Neurofibromatosis type 1\". I confirm both mappings now for final output, with a high degree of confidence. I have reviewed the entire schema and I am confident in my mapping choices for all the inputs.\n\n\n**Revising Sarcoma Mapping**\n\nI'm revisiting the \"sarcoma\" mapping, considering all options in the schema. While \"Malignant Peripheral Nerve Sheath Tumor\" and \"Fibrosarcoma\" exist, the instruction to narrow suggests \"Sarcoma\" is the best fit for just \"sarcoma\". With that resolved, \"whole exome sequencing\" is the direct map for the assay. Given the dataset is likely NF-focused, the diagnosis should map to \"Neurofibromatosis type 1\".\n\n\n**Refining Schema Mappings**\n\nI've finalized my schema mappings.  I'm now confident that \"sarcoma\" correctly maps to \"Sarcoma,\" \"exome sequencing\" to \"whole exome sequencing,\" and \"NF\" to \"Neurofibromatosis type 1.\" I've considered potential ambiguities and validated each choice against the schema, ensuring the most accurate representation of the input data.  The goal to narrow broad synonyms is achieved.\n\n\n**Mapping and Verification Completed**\n\nI've now re-examined the \"sarcoma\" mapping, choosing \"Sarcoma\" over more specific tumor types as per the instruction to narrow synonyms. The assay is confirmed as \"whole exome sequencing,\" and the final diagnosis is \"Neurofibromatosis type 1\". I'm now fully confident in the precision and accuracy of these mappings. The schema's structure is also confirmed correct.\n\n\n**Constructing the Final JSON**\n\nI am now constructing the final JSON output. After careful review, the mappings are confirmed: \"sarcoma\" to \"Sarcoma,\" \"exome sequencing\" to \"whole exome sequencing,\" and \"NF\" to \"Neurofibromatosis type 1.\" I've considered potential alternatives, but these mappings provide the best representation within the schema, fulfilling the requirement to narrow the original input terms. The JSON is built and verified.\n\n\n**Building the Final Output**\n\nI'm now fully focused on finalizing the output. After re-reviewing the mappings, I've confirmed that \"sarcoma\" directly translates to \"Sarcoma,\" and \"exome sequencing\" is best mapped to \"whole exome sequencing\". The most precise mapping for \"NF\" within the schema is \"Neurofibromatosis type 1.\" I'm confident in these choices as the most specific and accurate, as they adhere to the instruction to narrow broad synonyms. The JSON is built and verified.\n\n\n**Finalizing Mapping Decisions**\n\nI'm now fully confident about my final mappings. Re-evaluating the \"targeted sequencing\" option, I stick with \"whole exome sequencing\". The choice of \"sarcoma\" directly translates \"Sarcoma\" and that's the correct decision.  I have also reviewed and confirmed that \"Neurofibromatosis type 1\" for \"NF\" accurately narrows the input term. Everything is consistent.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2559,
              "completion_tokens": 3349,
              "total_tokens": 5908,
              "prompt_tokens_details": {
                "cached_tokens": 0
              },
              "completion_tokens_details": {
                "reasoning_tokens": 3306,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2559,
          "output_tokens": 3349,
          "total_tokens": 5908
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 2,
        "input": {
          "diagnosis": "Neurofibromatoses",
          "assay": "assay by high throughput sequencer",
          "tumorType": "Nerve Sheath Neoplasm"
        },
        "response": {
          "success": true,
          "content": "",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2568,
            "outputTokens": 4095,
            "totalTokens": 6663
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583680-z2kAD8gJaPfjnByd3J08",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583680,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "length",
                "native_finish_reason": "MAX_TOKENS",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "",
                  "refusal": null,
                  "reasoning": "**Narrowing Down Terms**\n\nI'm currently focused on mapping the provided broad terms, like \"Neurofibromatoses,\" \"assay by high throughput sequencer,\" and \"Nerve She\" to more precise, controlled vocabulary within the Target Schema. I'm prioritizing accuracy and relevance, so that the mapped terms remain as consistent with the user's data as possible. The next step is evaluating the degree of success, and iterating on the mapping strategy.\n\n\n**Mapping the Concepts**\n\nI've been analyzing the Target Schema options in relation to \"Neurofibromatoses,\" and it seems that \"Neurofibromatosis type 1\" is the most appropriate, likely default mapping without additional clarification. Further, I'm considering the nuances in \"assay by high throughput sequencer\" and how it translates to the schema options. I'm focusing on the term's core meaning - high-throughput sequencing - to select the best corresponding schema option. \"Nerve She\" is leading me to consider diagnostic features within the schema, as the context is strongly oriented towards pathology.\n\n\n**Clarifying Neurofibromatoses**\n\nI'm reconsidering the initial mapping of \"Neurofibromatoses\" given the potential for missing information. Recognizing \"Neurofibromatoses\" encompasses NF1, NF2, and Schwannomatosis, I'm now evaluating whether a generic fit or the most common type is appropriate, particularly in the absence of a \"Neurofibromatosis-NOS\" equivalent. The presence of \"Nerve Sheath Neoplasm\" strongly suggests a tumor context, guiding the selection process.\n\n\n**Evaluating Assay Types**\n\nI'm now focusing on \"assay by high throughput sequencer.\" Considering the context and noting that \"RNA-seq\" is an option within the Target Schema, I'm leaning towards that mapping, as it's a direct equivalent in some ontologies. \"Targeted sequencing\" appears potentially too narrow given the broader input. I'm also re-evaluating the `tumorType` options and how \"Nerve Sheath Neoplasm\" should be refined, especially in light of the diagnosis of \"Neurofibromatoses\" not definitively specifying a subtype.\n\n\n**Refining Assay Selection**\n\nI'm now zeroing in on the \"assay\" term, re-evaluating options considering the data portal's context. \"RNA-seq\" remains a strong contender for \"assay by high throughput sequencer,\" given its frequent use in expression profiling. The \"next generation targeted sequencing\" option is potentially too specific for the initial broad term. I need to balance precision with the initial lack of granularity provided about the sequencing application, as the schema's derivation from the NF Data Portal affects term selection.\n\n\n**Finalizing Term Mappings**\n\nI've been working to pin down the best mappings based on the specific context and available schema terms. Given that \"Neurofibromatoses\" often points to NF1 as the default, I'm sticking with that for now. \"RNA-seq\" is a solid choice for \"assay by high throughput sequencer,\" especially in the absence of more granular input. For \"Nerve Sheath Neoplasm,\" I'm now leaning towards \"Neurofibroma\" or \"Schwannoma\" based on the subtype of neurofibromatosis suggested by the clinical context. \"Malignant Peripheral Nerve Sheath Tumor\" won't be appropriate unless \"Malignant\" is explicitly stated. The `diagnosis` option needs to be addressed next.\n\n\n**Evaluating Diagnosis Options**\n\nI'm now focusing on \"Nerve Sheath Neoplasm\" and its corresponding diagnosis options within the schema. With the user context, I am considering \"Neurofibroma\" and \"Schwannoma\" as potential mappings if there are no specific markers for \"Malignant Peripheral Nerve Sheath Tumor\" indicated. I'm prioritizing accuracy in the schema selection given the context is a broad \"Neurofibromatoses\" patient and not explicitly a MPNST case. I must determine if the default for this schema in such cases is best mapped.\n\n\n**Selecting Schema Options**\n\nI'm now determining which diagnosis options best represent \"Nerve Sheath Neoplasm\" in this specific scenario. Recognizing that \"Malignant Peripheral Nerve Sheath Tumor\" is a possible mapping, I need to evaluate if it's the most appropriate or if \"Neurofibroma\" is a better fit given the input's context. I am considering the user's intent to capture the specific disease context within the `diagnosis` field. I must also take into account the user's description and whether or not it warrants a default value or requires a more nuanced term, considering the patient history.\n\n\n**Finalizing Diagnosis Choices**\n\nI'm now evaluating the diagnosis of \"Nerve Sheath Neoplasm.\" Given that both \"Neurofibroma\" and \"Schwannoma\" are nerve sheath tumors, and with the context suggesting NF1, I'm considering \"Neurofibroma\" as the primary choice, as it is most prevalent. However, \"Malignant Peripheral Nerve Sheath Tumor\" is the more severe type, and a common focus of research. If precision is required, I have to ensure the patient's record is updated. It looks like an \"Unknown\" option might be the best match given that these are tumor types are all possible and depend on the patient's individual diagnosis.\n\n\n**Selecting MPNST Mapping**\n\nI'm now zeroing in on a precise mapping for \"Nerve Sheath Neoplasm.\" Recognizing it often indicates MPNST in this data portal context, I'm leaning toward \"Malignant Peripheral Nerve Sheath Tumor\" as the most specific and accurate. While \"Neurofibroma\" and \"Schwannoma\" are possible, the focus on malignancy within \"Nerve Sheath Neoplasm\" strengthens this selection. Based on NF-OSI, \"Malignant Peripheral Nerve Sheath Tumor\" is the best option given the implied malignant context.\n\n\n**Confirming the Diagnosis**\n\nI'm now focusing on the 'Nerve Sheath Neoplasm' mapping. Reviewing the NF-OSI/Synapse context, I'm confident 'Malignant Peripheral Nerve Sheath Tumor' is the best fit, as 'Nerve Sheath Neoplasm' often implies it. I've re-examined the NCIT hierarchy for clarification, reinforcing this choice given the schema's nuances. This specific diagnosis reflects the tumor type and patient context.\n\n\n**Mapping MPNST Context**\n\nI'm now evaluating \"Nerve Sheath Neoplasm\". Given the hypothesis of MPNST, the choice of \"Malignant Peripheral Nerve Sheath Tumor\" aligns best in the schema. Further confirmation is needed from the user's data; however, this is the most likely tumor type given the context of neurofibromatosis and the absence of a more specific tumor type specification. The choice to default to Neurofibromatosis type 1 is predicated on its strong association with MPNST.\n\n\n**Prioritizing Precision in Mapping**\n\nI'm now focusing on re-evaluating the 'tumorType' options, given the initial term \"Nerve Sheath Neoplasm.\" \"Neurofibroma\" is a good alternative and is associated with NF1. However, since the term indicates a tumor requiring a distinct classification and often suggests malignancy, I'm now leaning towards \"Malignant Peripheral Nerve Sheath Tumor\" as the most precise mapping within the Target Schema, reflecting its complexity and malignant potential. I've re-examined the synonyms, and the provided schema. The synonym search led me to believe \"MPNST\" is the most specific.\n\n\n**Confirming the Mappings**\n\nI've been re-evaluating the mappings to ensure they accurately reflect the context. After cross-referencing the schema options with the NF-OSI data dictionary mappings, I am now more confident in selecting \"Neurofibromatosis type 1\" for `diagnosis`, \"RNA-seq\" for `assay`, and \"Malignant Peripheral Nerve Sheath Tumor\" for `tumorType`. These choices account for the most common interpretations and the specific nuances of the data, and reflect the likely data context. I am ready to move forward.\n\n\n**Finalizing Schema Selections**\n\nI'm now determining the most appropriate `assay` choice. Despite the broader definition of \"assay by high throughput sequencer,\" I'm leaning towards \"RNA-seq\" due to the specific data context of the NF Data Portal, where RNA sequencing is very common. While this could be overly specific, it reflects the typical data type. Additionally, the default mapping \"Neurofibromatosis type 1\" and \"Malignant Peripheral Nerve Sheath Tumor\" for `diagnosis` and `tumorType` respectively seem accurate given the likely context.\n\n\n**Choosing the Best Assay**\n\nI'm solidifying my approach to \"assay by high throughput sequencer.\" Considering that the existing context focuses on NF-OSI data, which typically involves RNA analysis, I believe that \"RNA-seq\" is the strongest contender. This term is explicit in the schema. This mapping reflects the likelihood and general approach to high throughput sequencing within this context. \n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Narrowing Down Terms**\n\nI'm currently focused on mapping the provided broad terms, like \"Neurofibromatoses,\" \"assay by high throughput sequencer,\" and \"Nerve She\" to more precise, controlled vocabulary within the Target Schema. I'm prioritizing accuracy and relevance, so that the mapped terms remain as consistent with the user's data as possible. The next step is evaluating the degree of success, and iterating on the mapping strategy.\n\n\n**Mapping the Concepts**\n\nI've been analyzing the Target Schema options in relation to \"Neurofibromatoses,\" and it seems that \"Neurofibromatosis type 1\" is the most appropriate, likely default mapping without additional clarification. Further, I'm considering the nuances in \"assay by high throughput sequencer\" and how it translates to the schema options. I'm focusing on the term's core meaning - high-throughput sequencing - to select the best corresponding schema option. \"Nerve She\" is leading me to consider diagnostic features within the schema, as the context is strongly oriented towards pathology.\n\n\n**Clarifying Neurofibromatoses**\n\nI'm reconsidering the initial mapping of \"Neurofibromatoses\" given the potential for missing information. Recognizing \"Neurofibromatoses\" encompasses NF1, NF2, and Schwannomatosis, I'm now evaluating whether a generic fit or the most common type is appropriate, particularly in the absence of a \"Neurofibromatosis-NOS\" equivalent. The presence of \"Nerve Sheath Neoplasm\" strongly suggests a tumor context, guiding the selection process.\n\n\n**Evaluating Assay Types**\n\nI'm now focusing on \"assay by high throughput sequencer.\" Considering the context and noting that \"RNA-seq\" is an option within the Target Schema, I'm leaning towards that mapping, as it's a direct equivalent in some ontologies. \"Targeted sequencing\" appears potentially too narrow given the broader input. I'm also re-evaluating the `tumorType` options and how \"Nerve Sheath Neoplasm\" should be refined, especially in light of the diagnosis of \"Neurofibromatoses\" not definitively specifying a subtype.\n\n\n**Refining Assay Selection**\n\nI'm now zeroing in on the \"assay\" term, re-evaluating options considering the data portal's context. \"RNA-seq\" remains a strong contender for \"assay by high throughput sequencer,\" given its frequent use in expression profiling. The \"next generation targeted sequencing\" option is potentially too specific for the initial broad term. I need to balance precision with the initial lack of granularity provided about the sequencing application, as the schema's derivation from the NF Data Portal affects term selection.\n\n\n**Finalizing Term Mappings**\n\nI've been working to pin down the best mappings based on the specific context and available schema terms. Given that \"Neurofibromatoses\" often points to NF1 as the default, I'm sticking with that for now. \"RNA-seq\" is a solid choice for \"assay by high throughput sequencer,\" especially in the absence of more granular input. For \"Nerve Sheath Neoplasm,\" I'm now leaning towards \"Neurofibroma\" or \"Schwannoma\" based on the subtype of neurofibromatosis suggested by the clinical context. \"Malignant Peripheral Nerve Sheath Tumor\" won't be appropriate unless \"Malignant\" is explicitly stated. The `diagnosis` option needs to be addressed next.\n\n\n**Evaluating Diagnosis Options**\n\nI'm now focusing on \"Nerve Sheath Neoplasm\" and its corresponding diagnosis options within the schema. With the user context, I am considering \"Neurofibroma\" and \"Schwannoma\" as potential mappings if there are no specific markers for \"Malignant Peripheral Nerve Sheath Tumor\" indicated. I'm prioritizing accuracy in the schema selection given the context is a broad \"Neurofibromatoses\" patient and not explicitly a MPNST case. I must determine if the default for this schema in such cases is best mapped.\n\n\n**Selecting Schema Options**\n\nI'm now determining which diagnosis options best represent \"Nerve Sheath Neoplasm\" in this specific scenario. Recognizing that \"Malignant Peripheral Nerve Sheath Tumor\" is a possible mapping, I need to evaluate if it's the most appropriate or if \"Neurofibroma\" is a better fit given the input's context. I am considering the user's intent to capture the specific disease context within the `diagnosis` field. I must also take into account the user's description and whether or not it warrants a default value or requires a more nuanced term, considering the patient history.\n\n\n**Finalizing Diagnosis Choices**\n\nI'm now evaluating the diagnosis of \"Nerve Sheath Neoplasm.\" Given that both \"Neurofibroma\" and \"Schwannoma\" are nerve sheath tumors, and with the context suggesting NF1, I'm considering \"Neurofibroma\" as the primary choice, as it is most prevalent. However, \"Malignant Peripheral Nerve Sheath Tumor\" is the more severe type, and a common focus of research. If precision is required, I have to ensure the patient's record is updated. It looks like an \"Unknown\" option might be the best match given that these are tumor types are all possible and depend on the patient's individual diagnosis.\n\n\n**Selecting MPNST Mapping**\n\nI'm now zeroing in on a precise mapping for \"Nerve Sheath Neoplasm.\" Recognizing it often indicates MPNST in this data portal context, I'm leaning toward \"Malignant Peripheral Nerve Sheath Tumor\" as the most specific and accurate. While \"Neurofibroma\" and \"Schwannoma\" are possible, the focus on malignancy within \"Nerve Sheath Neoplasm\" strengthens this selection. Based on NF-OSI, \"Malignant Peripheral Nerve Sheath Tumor\" is the best option given the implied malignant context.\n\n\n**Confirming the Diagnosis**\n\nI'm now focusing on the 'Nerve Sheath Neoplasm' mapping. Reviewing the NF-OSI/Synapse context, I'm confident 'Malignant Peripheral Nerve Sheath Tumor' is the best fit, as 'Nerve Sheath Neoplasm' often implies it. I've re-examined the NCIT hierarchy for clarification, reinforcing this choice given the schema's nuances. This specific diagnosis reflects the tumor type and patient context.\n\n\n**Mapping MPNST Context**\n\nI'm now evaluating \"Nerve Sheath Neoplasm\". Given the hypothesis of MPNST, the choice of \"Malignant Peripheral Nerve Sheath Tumor\" aligns best in the schema. Further confirmation is needed from the user's data; however, this is the most likely tumor type given the context of neurofibromatosis and the absence of a more specific tumor type specification. The choice to default to Neurofibromatosis type 1 is predicated on its strong association with MPNST.\n\n\n**Prioritizing Precision in Mapping**\n\nI'm now focusing on re-evaluating the 'tumorType' options, given the initial term \"Nerve Sheath Neoplasm.\" \"Neurofibroma\" is a good alternative and is associated with NF1. However, since the term indicates a tumor requiring a distinct classification and often suggests malignancy, I'm now leaning towards \"Malignant Peripheral Nerve Sheath Tumor\" as the most precise mapping within the Target Schema, reflecting its complexity and malignant potential. I've re-examined the synonyms, and the provided schema. The synonym search led me to believe \"MPNST\" is the most specific.\n\n\n**Confirming the Mappings**\n\nI've been re-evaluating the mappings to ensure they accurately reflect the context. After cross-referencing the schema options with the NF-OSI data dictionary mappings, I am now more confident in selecting \"Neurofibromatosis type 1\" for `diagnosis`, \"RNA-seq\" for `assay`, and \"Malignant Peripheral Nerve Sheath Tumor\" for `tumorType`. These choices account for the most common interpretations and the specific nuances of the data, and reflect the likely data context. I am ready to move forward.\n\n\n**Finalizing Schema Selections**\n\nI'm now determining the most appropriate `assay` choice. Despite the broader definition of \"assay by high throughput sequencer,\" I'm leaning towards \"RNA-seq\" due to the specific data context of the NF Data Portal, where RNA sequencing is very common. While this could be overly specific, it reflects the typical data type. Additionally, the default mapping \"Neurofibromatosis type 1\" and \"Malignant Peripheral Nerve Sheath Tumor\" for `diagnosis` and `tumorType` respectively seem accurate given the likely context.\n\n\n**Choosing the Best Assay**\n\nI'm solidifying my approach to \"assay by high throughput sequencer.\" Considering that the existing context focuses on NF-OSI data, which typically involves RNA analysis, I believe that \"RNA-seq\" is the strongest contender. This term is explicit in the schema. This mapping reflects the likelihood and general approach to high throughput sequencing within this context. \n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2568,
              "completion_tokens": 4095,
              "total_tokens": 6663,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 4095,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole genome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2568,
          "output_tokens": 4095,
          "total_tokens": 6663
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 3,
        "input": {
          "diagnosis": "neurocutaneous syndrome",
          "assay": "spectroscopy",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2559,
            "outputTokens": 4095,
            "totalTokens": 6654
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583716-RaKm3QzW3odjYB9yCHip",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583716,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "length",
                "native_finish_reason": "MAX_TOKENS",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "",
                  "refusal": null,
                  "reasoning": "**Refining the Approach**\n\nI'm now focusing on narrowing the broad term \"neurocutaneous syndrome\" to a specific, controlled vocabulary term from the provided schema. I'm exploring methods to map the synonym to the precise definition within the schema. Currently, I'm thinking of methods to match the closest match with the use of natural language processing or a dedicated dictionary.\n\n\n**Mapping Term Precision**\n\nI've been analyzing the target schema for a precise diagnosis mapping. The term \"neurocutaneous syndrome\" presents a challenge, as it encompasses multiple conditions. Considering the options, and recalling the prior \"Unknown\" placeholder, I'm now leaning towards \"Neurofibromatosis type 1\" as the closest specific match, despite the lack of direct specificity. I must revisit and analyze the context, but I have a strong preference towards a single solution.\n\n\n**Exploring Nuances Further**\n\nI'm now revisiting the \"Neurocutaneous syndrome\" mapping problem, with \"Schwannomatosis\" now on the radar as a potential fit. Recognizing the potential for this to be a placeholder term, I'm carefully considering the context of the available schema options. The absence of a general \"Neurofibromatosis\" entry, but presence of \"Neurofibromatosis type 1\" and \"Schwannomatosis,\" adds complexity. If the input is only \"neurocutaneous syndrome,\" I'm leaning toward the \"Unknown\" placeholder as the safest mapping, because of the broadness of the term. The prompt may assume the input is the \"intended\" synonym and that I'm trying to deduce a more accurate match.\n\n\n**Refining Mapping Strategy**\n\nI'm now focusing on specific data curation rules relevant to NF data, like NF Data Portal guidelines. Analyzing the `tumorType` and `assay` fields, along with re-evaluating \"neurocutaneous syndrome,\" has led me to re-consider the context. Based on the prompt's instruction to \"narrow broad synonyms\", I am leaning towards using \"Unknown\" in this case as the safest and most accurate response, as I cannot deduce the more precise term from the information provided.\n\n\n**Analyzing Field Context**\n\nI'm now back on the field context, exploring the `assay` and `tumorType` to refine my mapping. \"Spectroscopy\" poses a challenge because of its lack of specificity within the schema's available options. However, \"unknown\" directly maps to \"Unknown\" in the `tumorType` field, providing a clear match. I'm now reconsidering the `diagnosis` mapping, acknowledging that even \"Neurofibromatosis type 1\" might be a risky assumption for a vague \"neurocutaneous syndrome.\"\n\n\n**Interpreting Assay Data**\n\nI'm now pondering the \"spectroscopy\" assay, considering its various interpretations. Given the clinical nature of this data, I'm leaning towards \"magnetic resonance spectroscopy.\" I've narrowed it down to potential schema matches, and am now comparing the \"magnetic resonance spectroscopy\" option to other related matches to find the best fit. I'm now revisiting the broader prompt instructions to ensure I am making the appropriate mapping from the possible matches.\n\n\n**Evaluating Uncertainties**\n\nI'm now focusing on mapping the diagnosis field. Given the input \"neurocutaneous syndrome,\" I'm facing uncertainty because it's a superclass and could represent different specific conditions, but without information. Considering the `tumorType` field, where \"unknown\" confidently maps to \"Unknown,\" I'm prioritizing accuracy. I'm leaning toward mapping \"neurocutaneous syndrome\" to **Unknown** in the absence of explicit context or specific mapping rules provided in the prompt, focusing on the principle of narrowing broad synonyms.\n\n\n**Evaluating Best Fit**\n\nI'm now re-evaluating the \"neurocutaneous syndrome\" mapping problem. Given the NF-OSI context, the schema's inclusion of NF1- and NF2-associated tumor types, and the prompt's instruction to narrow broad synonyms, I am leaning toward mapping \"neurocutaneous syndrome\" to \"Neurofibromatosis type 1\". This decision stems from the understanding that \"neurocutaneous syndrome\" is likely a legacy term. However, the lack of complete data and the presence of options like \"Schwannomatosis\" make this an educated, not definitive, assumption.\n\n\n**Refining Diagnosis Strategy**\n\nI'm now revisiting the \"narrowing\" concept, analyzing the existing schemas. Since I have to \"narrow\" a broad term, and given the schema's NF focus, \"Neurofibromatosis type 1\" seems the closest match. However, the schema also includes \"Unknown,\" making me reconsider if the safest approach is to use \"Unknown\" to map the provided term. I am still trying to determine how to proceed.\n\n\n**Evaluating Specificity Further**\n\nI'm now revisiting the \"neurocutaneous syndrome\" diagnosis, considering that it's often a synonym for **Neurofibromatosis type 1**. Given the prompt's instruction to narrow broad terms, and the schema's focus on NF, I'm leaning towards the mapping. The ICD-10 code Q85.0 further supports this. I'm carefully weighing the possibility of \"Unknown\" but now believe \"Neurofibromatosis type 1\" is a better approximation in this context.\n\n\n**Determining the Closest Matches**\n\nI'm now focusing on the \"spectroscopy\" term and its mapping. Considering the tumor research context, I'm leaning toward \"mass spectrometry\" as the best match, as it aligns with the available schema options. The previous analysis confirms the need for a precise term. I will now integrate this mapping into the overall mapping approach.\n\n\n**Mapping Assay Specificity**\n\nI'm now determining the mapping of the \"spectroscopy\" assay, considering its various contexts. Given the tumor research focus and the presence of \"unknown\" in the tumor type, I'm leaning toward \"magnetic resonance spectroscopy\" as the best match. I'm now comparing this match with the other options, and I will be re-evaluating the broader prompt instructions to ensure I am making the appropriate mapping from possible matches.\n\n\n**Analyzing Potential Matches**\n\nI'm now focusing on mapping the diagnosis field. Given \"neurocutaneous syndrome,\" I've revisited \"Neurofibromatosis type 1\" as the closest match, considering the prompt's instruction to narrow broad synonyms within the NF research context. I'm prioritizing accuracy, especially considering the likely legacy use of \"neurocutaneous syndrome.\" I'm also ensuring the target field casing (\"Unknown\") aligns with the schema.\n\n\n**Evaluating Data Integrity**\n\nI'm now focusing on ensuring data integrity. I'm choosing \"Neurofibromatosis type 1\" for the diagnosis, and \"Unknown\" for the `tumorType`. For the assay, given the schema's available options, I am leaning toward \"mass spectrometry\". However, I am now reviewing the prompt again, and double-checking that my mapping decisions align with the NF-OSI project's goals of precision. I'll need to double check the previous mapping decisions to be precise.\n\n\n**Determining the Precise Match**\n\nI'm now determining the best match for \"spectroscopy\" based on the context provided. After reconsidering the previous analysis and the nature of the prompt, I'm leaning toward mapping \"spectroscopy\" to **magnetic resonance spectroscopy**, reflecting the NF-OSI project's focus. This choice aligns with the metadata curation assistant's role in a specific dataset context, often found in NF Data Portal. I am now double-checking my previous decisions. I will map \"Neurofibromatosis type 1\" to diagnosis and \"Unknown\" to `tumorType` to maintain accuracy.\n\n\n**Selecting Final Mappings**\n\nI'm now consolidating my final mappings based on a review of the schema and the prompt's instructions. Having evaluated potential synonyms, I'm confident in mapping \"atypical neurofibroma\" to \"High Grade Malignant Peripheral Nerve Sheath Tumor\", \"Juvenile myelomonocytic leukemia\" to itself, and \"Noonan Syndrome\" to itself. I will map \"Neurocutaneous syndrome\" to \"Neurofibromatosis type 1\" given its prevalence and my prior analysis. For the assay, I am leaning to map \"spectroscopy\" to \"magnetic resonance spectroscopy\" for its common usage. Finally, \"unknown\" for `tumorType` will be mapped to \"Unknown\".\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Refining the Approach**\n\nI'm now focusing on narrowing the broad term \"neurocutaneous syndrome\" to a specific, controlled vocabulary term from the provided schema. I'm exploring methods to map the synonym to the precise definition within the schema. Currently, I'm thinking of methods to match the closest match with the use of natural language processing or a dedicated dictionary.\n\n\n**Mapping Term Precision**\n\nI've been analyzing the target schema for a precise diagnosis mapping. The term \"neurocutaneous syndrome\" presents a challenge, as it encompasses multiple conditions. Considering the options, and recalling the prior \"Unknown\" placeholder, I'm now leaning towards \"Neurofibromatosis type 1\" as the closest specific match, despite the lack of direct specificity. I must revisit and analyze the context, but I have a strong preference towards a single solution.\n\n\n**Exploring Nuances Further**\n\nI'm now revisiting the \"Neurocutaneous syndrome\" mapping problem, with \"Schwannomatosis\" now on the radar as a potential fit. Recognizing the potential for this to be a placeholder term, I'm carefully considering the context of the available schema options. The absence of a general \"Neurofibromatosis\" entry, but presence of \"Neurofibromatosis type 1\" and \"Schwannomatosis,\" adds complexity. If the input is only \"neurocutaneous syndrome,\" I'm leaning toward the \"Unknown\" placeholder as the safest mapping, because of the broadness of the term. The prompt may assume the input is the \"intended\" synonym and that I'm trying to deduce a more accurate match.\n\n\n**Refining Mapping Strategy**\n\nI'm now focusing on specific data curation rules relevant to NF data, like NF Data Portal guidelines. Analyzing the `tumorType` and `assay` fields, along with re-evaluating \"neurocutaneous syndrome,\" has led me to re-consider the context. Based on the prompt's instruction to \"narrow broad synonyms\", I am leaning towards using \"Unknown\" in this case as the safest and most accurate response, as I cannot deduce the more precise term from the information provided.\n\n\n**Analyzing Field Context**\n\nI'm now back on the field context, exploring the `assay` and `tumorType` to refine my mapping. \"Spectroscopy\" poses a challenge because of its lack of specificity within the schema's available options. However, \"unknown\" directly maps to \"Unknown\" in the `tumorType` field, providing a clear match. I'm now reconsidering the `diagnosis` mapping, acknowledging that even \"Neurofibromatosis type 1\" might be a risky assumption for a vague \"neurocutaneous syndrome.\"\n\n\n**Interpreting Assay Data**\n\nI'm now pondering the \"spectroscopy\" assay, considering its various interpretations. Given the clinical nature of this data, I'm leaning towards \"magnetic resonance spectroscopy.\" I've narrowed it down to potential schema matches, and am now comparing the \"magnetic resonance spectroscopy\" option to other related matches to find the best fit. I'm now revisiting the broader prompt instructions to ensure I am making the appropriate mapping from the possible matches.\n\n\n**Evaluating Uncertainties**\n\nI'm now focusing on mapping the diagnosis field. Given the input \"neurocutaneous syndrome,\" I'm facing uncertainty because it's a superclass and could represent different specific conditions, but without information. Considering the `tumorType` field, where \"unknown\" confidently maps to \"Unknown,\" I'm prioritizing accuracy. I'm leaning toward mapping \"neurocutaneous syndrome\" to **Unknown** in the absence of explicit context or specific mapping rules provided in the prompt, focusing on the principle of narrowing broad synonyms.\n\n\n**Evaluating Best Fit**\n\nI'm now re-evaluating the \"neurocutaneous syndrome\" mapping problem. Given the NF-OSI context, the schema's inclusion of NF1- and NF2-associated tumor types, and the prompt's instruction to narrow broad synonyms, I am leaning toward mapping \"neurocutaneous syndrome\" to \"Neurofibromatosis type 1\". This decision stems from the understanding that \"neurocutaneous syndrome\" is likely a legacy term. However, the lack of complete data and the presence of options like \"Schwannomatosis\" make this an educated, not definitive, assumption.\n\n\n**Refining Diagnosis Strategy**\n\nI'm now revisiting the \"narrowing\" concept, analyzing the existing schemas. Since I have to \"narrow\" a broad term, and given the schema's NF focus, \"Neurofibromatosis type 1\" seems the closest match. However, the schema also includes \"Unknown,\" making me reconsider if the safest approach is to use \"Unknown\" to map the provided term. I am still trying to determine how to proceed.\n\n\n**Evaluating Specificity Further**\n\nI'm now revisiting the \"neurocutaneous syndrome\" diagnosis, considering that it's often a synonym for **Neurofibromatosis type 1**. Given the prompt's instruction to narrow broad terms, and the schema's focus on NF, I'm leaning towards the mapping. The ICD-10 code Q85.0 further supports this. I'm carefully weighing the possibility of \"Unknown\" but now believe \"Neurofibromatosis type 1\" is a better approximation in this context.\n\n\n**Determining the Closest Matches**\n\nI'm now focusing on the \"spectroscopy\" term and its mapping. Considering the tumor research context, I'm leaning toward \"mass spectrometry\" as the best match, as it aligns with the available schema options. The previous analysis confirms the need for a precise term. I will now integrate this mapping into the overall mapping approach.\n\n\n**Mapping Assay Specificity**\n\nI'm now determining the mapping of the \"spectroscopy\" assay, considering its various contexts. Given the tumor research focus and the presence of \"unknown\" in the tumor type, I'm leaning toward \"magnetic resonance spectroscopy\" as the best match. I'm now comparing this match with the other options, and I will be re-evaluating the broader prompt instructions to ensure I am making the appropriate mapping from possible matches.\n\n\n**Analyzing Potential Matches**\n\nI'm now focusing on mapping the diagnosis field. Given \"neurocutaneous syndrome,\" I've revisited \"Neurofibromatosis type 1\" as the closest match, considering the prompt's instruction to narrow broad synonyms within the NF research context. I'm prioritizing accuracy, especially considering the likely legacy use of \"neurocutaneous syndrome.\" I'm also ensuring the target field casing (\"Unknown\") aligns with the schema.\n\n\n**Evaluating Data Integrity**\n\nI'm now focusing on ensuring data integrity. I'm choosing \"Neurofibromatosis type 1\" for the diagnosis, and \"Unknown\" for the `tumorType`. For the assay, given the schema's available options, I am leaning toward \"mass spectrometry\". However, I am now reviewing the prompt again, and double-checking that my mapping decisions align with the NF-OSI project's goals of precision. I'll need to double check the previous mapping decisions to be precise.\n\n\n**Determining the Precise Match**\n\nI'm now determining the best match for \"spectroscopy\" based on the context provided. After reconsidering the previous analysis and the nature of the prompt, I'm leaning toward mapping \"spectroscopy\" to **magnetic resonance spectroscopy**, reflecting the NF-OSI project's focus. This choice aligns with the metadata curation assistant's role in a specific dataset context, often found in NF Data Portal. I am now double-checking my previous decisions. I will map \"Neurofibromatosis type 1\" to diagnosis and \"Unknown\" to `tumorType` to maintain accuracy.\n\n\n**Selecting Final Mappings**\n\nI'm now consolidating my final mappings based on a review of the schema and the prompt's instructions. Having evaluated potential synonyms, I'm confident in mapping \"atypical neurofibroma\" to \"High Grade Malignant Peripheral Nerve Sheath Tumor\", \"Juvenile myelomonocytic leukemia\" to itself, and \"Noonan Syndrome\" to itself. I will map \"Neurocutaneous syndrome\" to \"Neurofibromatosis type 1\" given its prevalence and my prior analysis. For the assay, I am leaning to map \"spectroscopy\" to \"magnetic resonance spectroscopy\" for its common usage. Finally, \"unknown\" for `tumorType` will be mapped to \"Unknown\".\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2559,
              "completion_tokens": 4095,
              "total_tokens": 6654,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 4095,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 2559,
          "output_tokens": 4095,
          "total_tokens": 6654
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 4,
        "input": {
          "diagnosis": "Not Applicable",
          "assay": "immunoassay",
          "tumorType": "neurofibroma"
        },
        "response": {
          "success": true,
          "content": "",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2559,
            "outputTokens": 4095,
            "totalTokens": 6654
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583754-cE1Nfv5eaFw1fgLKBu1r",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583754,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "length",
                "native_finish_reason": "MAX_TOKENS",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "",
                  "refusal": null,
                  "reasoning": "**Defining Synonym Scope**\n\nI'm currently focused on defining the scope of synonyms. My goal is to narrow down broad terms like \"immunoassay\" in the input data to fit the specifics of the target schema. I'm exploring methods to map these broad terms to a more refined vocabulary relevant to the schema's context. I'm considering the best strategy to accurately map these terms to a more relevant vocabulary.\n\n\n**Revising Scope Definition**\n\nI've revised the scope definition focus. Considering the \"diagnosis\" field, I initially identified \"Not Applicable\" as a controlled term and, therefore, potentially outside the realm of \"broad synonym\" narrowing. However, I've re-evaluated that \"Not Applicable\" is already in the schema. Unless context dictates otherwise, I'm keeping it as is. The tumor type is \"neurofibroma,\" but without more context, I'm maintaining the original value.\n\n\n**Assessing Assay Specificity**\n\nI've re-examined the 'assay' field. The input, 'immunoassay,' is, technically, a valid schema term. Yet, per the prompt, I need to narrow broad terms. I'm focusing on identifying a *more* specific assay type if possible. The schema offers choices like ELISA and immunohistochemistry. Since I lack additional context, I'm now contemplating strategies to deduce the *most* likely specific assay, if I must change from \"immunoassay\".\n\n\n**Re-Evaluating Input Specificity**\n\nI'm reconsidering the \"immunoassay\" term. While technically valid in the schema, the prompt demands narrowing broad terms. I need to determine if \"immunoassay\" is *truly* the most specific option here. The JSON input provides no other clues. I'm focusing on strategies to assess the necessity of re-mapping to a more specific assay type, even though no additional context is available. I'm currently leaning towards keeping \"immunoassay\" as is.\n\n\n**Analyzing Term Mapping**\n\nI'm now analyzing the direct mappings of input terms to schema enums. \"Not Applicable,\" \"immunoassay,\" and \"neurofibroma\" all seem to match schema values, with the case needing checking on \"neurofibroma.\" This is different from the usual term mapping. I'm checking the schema again to confirm that \"immunoassay\" is a valid and specific choice, as the instructions emphasized narrowing the scope.\n\n\n**Refining Assay Mapping**\n\nI'm now revisiting the \"assay\" field mapping. My focus is on determining if I *must* change the value. While \"immunoassay\" exists in the schema, the instructions emphasized narrowing broad terms. I need to determine if \"immunoassay\" is *truly* the most specific option here. If I can't deduce a more specific assay from the available input, I'll need to confirm if keeping \"immunoassay\" aligns with the prompt's intent, given the lack of context. I am now leaning towards keeping it as is.\n\n\n**Examining Tumor Specificity**\n\nI'm now diving into the `tumorType` field. The schema has \"Neurofibroma,\" \"Cutaneous Neurofibroma,\" and \"Plexiform Neurofibroma.\" The input is \"neurofibroma,\" which, after case correction, is a match for the general \"Neurofibroma\" and it is already in the schema. So, I don't need to change it further. I've re-confirmed that keeping it as \"Neurofibroma\" is the best option.\n\n\n**Determining Mapping Logic**\n\nI'm now determining the mapping logic for \"immunoassay.\" The prompt's emphasis on narrowing broad terms is clear, but the input is *already* \"immunoassay,\" which exists in the schema. I'm focusing on whether I can *deduce* a more specific assay type from the absence of other context. If not, I'm leaning toward keeping \"immunoassay\" as is, as it's a valid schema term. I will be confirming this.\n\n\n**Verifying Term Fidelity**\n\nI'm now focused on the exact term mappings. I'm verifying the \"immunoassay\" mapping again. Since the schema includes \"immunoassay\" as a valid option, and there's no additional context to suggest a more specific assay type, I'm confirming that \"immunoassay\" is the most appropriate choice to use for the output. I also re-checked the `tumorType` of \"Neurofibroma\" and confirming it is valid.\n\n\n**Reassessing Schema Alignment**\n\nI'm now reassessing the term \"immunoassay\". I re-evaluated the context again. I realize that the target output should mirror existing schema enumerations. I was debating a more granular term, but I see now that \"immunoassay\" is available in the schema. Given the lack of further information, I am more inclined to keep it as \"immunoassay\". I will verify that the prompt's instruction to narrow scope does not contradict with simply matching terms present in the schema.\n\n\n**Prioritizing Synonym Specificity**\n\nI'm now focusing on the \"immunoassay\" field. Despite \"immunoassay\" being a schema term, the prompt prioritizes narrowing broad synonyms. The lack of context leaves me unsure if a *more* specific assay is intended. I am re-evaluating whether \"immunoassay\" fulfills the intent of the instructions, given it is already in the schema.\n\n\n**Clarifying Assay Specificity**\n\nI'm now clarifying the assay mapping strategy. I'm focusing on the interplay between the \"narrow broad synonyms\" directive and the schema's direct enumeration. It seems \"immunoassay\" is the most specific option available within the schema given the constraints of the input. I will confirm that the prompt's instruction to narrow scope does not contradict with simply matching terms present in the schema. I'm prioritizing accuracy to schema values, given this lack of external context.\n\n\n**Finalizing Mapping Strategies**\n\nI am now finalizing the mapping logic. I've thoroughly re-examined the input terms \"immunoassay\", \"neurofibroma\", and \"Not Applicable\" against the schema. I've determined that all three terms are present in the schema. In the case of \"immunoassay\", I lack context for a more specific assay type, and thus will not make an assumption. I will ensure this choice is the most appropriate. I'm prioritizing direct schema alignment and avoiding unwarranted inferences.\n\n\n**Mapping Field Values**\n\nI'm now mapping the field values directly. I've confirmed that \"immunoassay\" is in the schema, as is \"Neurofibroma\" after case correction, and \"Not Applicable\". Since I have no context for further refinement, I'll avoid inferring additional information and stick to the schema's explicit terms. I am confident in these mappings given the context of the prompt.\n\n\n**Evaluating Input Fidelity**\n\nI'm now deep-diving into the 'diagnosis' field's mapping. The input provides \"Not Applicable,\" and I've considered alternatives like \"Unknown\" and more specific diagnoses. After careful review, I've confirmed that \"Not Applicable\" aligns best with the available context, despite the entity type's implication of possible diagnosis. I'm focusing on preserving the original value given the lack of sufficient information. My mapping strategy emphasizes schema adherence.\n\n\n**Prioritizing Input Accuracy**\n\nI'm now thoroughly examining the input terms. I will ensure that the current term assignments are the most appropriate. I'm focusing on \"immunoassay\" and confirming that I'm not over-interpreting the scope narrowing instructions. While the input specifies \"immunoassay\", I have no further context for specifying, say, ELISA, so I will stick with that. \"Neurofibroma\" is a good match, and \"Not Applicable\" needs no changes.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Defining Synonym Scope**\n\nI'm currently focused on defining the scope of synonyms. My goal is to narrow down broad terms like \"immunoassay\" in the input data to fit the specifics of the target schema. I'm exploring methods to map these broad terms to a more refined vocabulary relevant to the schema's context. I'm considering the best strategy to accurately map these terms to a more relevant vocabulary.\n\n\n**Revising Scope Definition**\n\nI've revised the scope definition focus. Considering the \"diagnosis\" field, I initially identified \"Not Applicable\" as a controlled term and, therefore, potentially outside the realm of \"broad synonym\" narrowing. However, I've re-evaluated that \"Not Applicable\" is already in the schema. Unless context dictates otherwise, I'm keeping it as is. The tumor type is \"neurofibroma,\" but without more context, I'm maintaining the original value.\n\n\n**Assessing Assay Specificity**\n\nI've re-examined the 'assay' field. The input, 'immunoassay,' is, technically, a valid schema term. Yet, per the prompt, I need to narrow broad terms. I'm focusing on identifying a *more* specific assay type if possible. The schema offers choices like ELISA and immunohistochemistry. Since I lack additional context, I'm now contemplating strategies to deduce the *most* likely specific assay, if I must change from \"immunoassay\".\n\n\n**Re-Evaluating Input Specificity**\n\nI'm reconsidering the \"immunoassay\" term. While technically valid in the schema, the prompt demands narrowing broad terms. I need to determine if \"immunoassay\" is *truly* the most specific option here. The JSON input provides no other clues. I'm focusing on strategies to assess the necessity of re-mapping to a more specific assay type, even though no additional context is available. I'm currently leaning towards keeping \"immunoassay\" as is.\n\n\n**Analyzing Term Mapping**\n\nI'm now analyzing the direct mappings of input terms to schema enums. \"Not Applicable,\" \"immunoassay,\" and \"neurofibroma\" all seem to match schema values, with the case needing checking on \"neurofibroma.\" This is different from the usual term mapping. I'm checking the schema again to confirm that \"immunoassay\" is a valid and specific choice, as the instructions emphasized narrowing the scope.\n\n\n**Refining Assay Mapping**\n\nI'm now revisiting the \"assay\" field mapping. My focus is on determining if I *must* change the value. While \"immunoassay\" exists in the schema, the instructions emphasized narrowing broad terms. I need to determine if \"immunoassay\" is *truly* the most specific option here. If I can't deduce a more specific assay from the available input, I'll need to confirm if keeping \"immunoassay\" aligns with the prompt's intent, given the lack of context. I am now leaning towards keeping it as is.\n\n\n**Examining Tumor Specificity**\n\nI'm now diving into the `tumorType` field. The schema has \"Neurofibroma,\" \"Cutaneous Neurofibroma,\" and \"Plexiform Neurofibroma.\" The input is \"neurofibroma,\" which, after case correction, is a match for the general \"Neurofibroma\" and it is already in the schema. So, I don't need to change it further. I've re-confirmed that keeping it as \"Neurofibroma\" is the best option.\n\n\n**Determining Mapping Logic**\n\nI'm now determining the mapping logic for \"immunoassay.\" The prompt's emphasis on narrowing broad terms is clear, but the input is *already* \"immunoassay,\" which exists in the schema. I'm focusing on whether I can *deduce* a more specific assay type from the absence of other context. If not, I'm leaning toward keeping \"immunoassay\" as is, as it's a valid schema term. I will be confirming this.\n\n\n**Verifying Term Fidelity**\n\nI'm now focused on the exact term mappings. I'm verifying the \"immunoassay\" mapping again. Since the schema includes \"immunoassay\" as a valid option, and there's no additional context to suggest a more specific assay type, I'm confirming that \"immunoassay\" is the most appropriate choice to use for the output. I also re-checked the `tumorType` of \"Neurofibroma\" and confirming it is valid.\n\n\n**Reassessing Schema Alignment**\n\nI'm now reassessing the term \"immunoassay\". I re-evaluated the context again. I realize that the target output should mirror existing schema enumerations. I was debating a more granular term, but I see now that \"immunoassay\" is available in the schema. Given the lack of further information, I am more inclined to keep it as \"immunoassay\". I will verify that the prompt's instruction to narrow scope does not contradict with simply matching terms present in the schema.\n\n\n**Prioritizing Synonym Specificity**\n\nI'm now focusing on the \"immunoassay\" field. Despite \"immunoassay\" being a schema term, the prompt prioritizes narrowing broad synonyms. The lack of context leaves me unsure if a *more* specific assay is intended. I am re-evaluating whether \"immunoassay\" fulfills the intent of the instructions, given it is already in the schema.\n\n\n**Clarifying Assay Specificity**\n\nI'm now clarifying the assay mapping strategy. I'm focusing on the interplay between the \"narrow broad synonyms\" directive and the schema's direct enumeration. It seems \"immunoassay\" is the most specific option available within the schema given the constraints of the input. I will confirm that the prompt's instruction to narrow scope does not contradict with simply matching terms present in the schema. I'm prioritizing accuracy to schema values, given this lack of external context.\n\n\n**Finalizing Mapping Strategies**\n\nI am now finalizing the mapping logic. I've thoroughly re-examined the input terms \"immunoassay\", \"neurofibroma\", and \"Not Applicable\" against the schema. I've determined that all three terms are present in the schema. In the case of \"immunoassay\", I lack context for a more specific assay type, and thus will not make an assumption. I will ensure this choice is the most appropriate. I'm prioritizing direct schema alignment and avoiding unwarranted inferences.\n\n\n**Mapping Field Values**\n\nI'm now mapping the field values directly. I've confirmed that \"immunoassay\" is in the schema, as is \"Neurofibroma\" after case correction, and \"Not Applicable\". Since I have no context for further refinement, I'll avoid inferring additional information and stick to the schema's explicit terms. I am confident in these mappings given the context of the prompt.\n\n\n**Evaluating Input Fidelity**\n\nI'm now deep-diving into the 'diagnosis' field's mapping. The input provides \"Not Applicable,\" and I've considered alternatives like \"Unknown\" and more specific diagnoses. After careful review, I've confirmed that \"Not Applicable\" aligns best with the available context, despite the entity type's implication of possible diagnosis. I'm focusing on preserving the original value given the lack of sufficient information. My mapping strategy emphasizes schema adherence.\n\n\n**Prioritizing Input Accuracy**\n\nI'm now thoroughly examining the input terms. I will ensure that the current term assignments are the most appropriate. I'm focusing on \"immunoassay\" and confirming that I'm not over-interpreting the scope narrowing instructions. While the input specifies \"immunoassay\", I have no further context for specifying, say, ELISA, so I will stick with that. \"Neurofibroma\" is a good match, and \"Not Applicable\" needs no changes.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2559,
              "completion_tokens": 4095,
              "total_tokens": 6654,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 4095,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Not Applicable",
          "assay": "immunohistochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2559,
          "output_tokens": 4095,
          "total_tokens": 6654
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 5,
        "input": {
          "diagnosis": "neurofibromatosis",
          "assay": "plate based reporter assay",
          "tumorType": "benign neurofibroma"
        },
        "response": {
          "success": true,
          "content": "",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2566,
            "outputTokens": 4095,
            "totalTokens": 6661
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583791-l1S1DcGCrY7OE2Hhipn3",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583791,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "length",
                "native_finish_reason": "MAX_TOKENS",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "",
                  "refusal": null,
                  "reasoning": "**Refining Synonyms**\n\nI'm currently focused on the challenge of refining broad synonyms into specific, controlled terminology. For instance, \"neurofibromatosis\" is a good start, but I need to determine the most precise term available in my knowledge base. The \"plate based reporter assay\" requires similar scrutiny, and \"benign neurofibroma\" may need further specification. The goal is accuracy and consistency.\n\n\n**Mapping Diagnosis to Terms**\n\nI've been analyzing the \"diagnosis\" field, specifically the input \"neurofibromatosis.\" My schema offers numerous options, including \"Neurofibromatosis type 1,\" \"NF2-related schwannomatosis,\" and others. Considering the context of \"benign neurofibroma,\" I've concluded that \"Neurofibromatosis type 1\" is the most accurate and appropriate specific term for this particular instance.\n\n\n**Identifying Precision Assay**\n\nI'm currently evaluating the \"plate based reporter assay\" input.  \"High-throughput cellular screening\" or \"cAMP-Glo Max Assay\" appear as key matches in my schema. Other assays listed don't fit the context, so I'm focusing on \"FLIPR high-throughput cellular screening\" and \"cAMP-Glo Max Assay.\" The best fit depends on nuances I need to extract.\n\n\n**Enumerating Assays**\n\nI've expanded my focus to include a wide array of assays. Now, I'm cataloging various assays, from methylation and miRNA arrays to more specific tests like the Von Frey test and TriKinetics assays. This process aims to increase the breadth of my understanding and improve accuracy in the long run. I am cross-referencing these assays with relevant data types like clinical data and Skindex scores.\n\n\n**Listing Assay Options**\n\nI'm currently compiling a comprehensive list of assays, encompassing STR, SNP, RPPA, and various sequencing methods like RNA-seq and ATAC-seq. I'm also including functional tests such as migration assays and those utilizing advanced technologies like CODEX and FTIR. I'm considering quantitative PCR, ELISA, and several image-based techniques.\n\n\n**Generating Assay Inventory**\n\nI'm currently focused on expanding my list of assays to include specific techniques like \"immunofluorescence,\" \"immunohistochemistry,\" and advanced methods like \"lncRNA-seq\" and \"oxBS-seq.\" I'm also considering techniques that involve optical and light methods, such as \"phase-contrast\" and \"laser\" techniques. The goal is to develop a complete inventory of relevant assays.\n\n\n**Discriminating Assays**\n\nI'm now zeroing in on \"FLIPR high-throughput cellular screening\" as the most precise descriptor for a \"plate based reporter assay,\" given its high-throughput nature. Contextually, \"cAMP-Glo Max Assay\" fits, but I'll favor FLIPR without additional data. I'm starting to differentiate between generic and precise terminology to ensure clarity.\n\n\n**Reconciling Terminology**\n\nI'm now delving into the \"plate based reporter assay\" input.  My analysis of NF-specific datasets and schema mappings suggests \"high content screen\" as a strong contender. However, the input's emphasis on \"reporter\" makes me re-evaluate, since \"FLIPR\" is in my schema. I'm considering \"cell viability assay\" and \"immunoassay\" as options. I have eliminated more specific terms such as \"cAMP-Glo Max Assay\" unless the context explicitly mentions cAMP.\n\n\n**Evaluating Assay Options**\n\nI'm currently re-examining my assay list, with particular focus on the \"FLIPR high-throughput cellular screening\" term. I'm exploring additional options like \"massively parallel reporter assay\" and \"compound screen,\" considering their relevance. Also, I am now including new options. The array-based assays will be considered later.\n\n\n**Broadening the Assay Scope**\n\nI'm now expanding my list of assay options. \"Reactive oxygen species assay,\" \"light scattering assay,\" \"focus forming assay,\" and \"feeding assay\" are now included, as are \"fluorescence microscopy assay\" and \"current clamp assay.\" My goal is to assemble a comprehensive list to ensure accuracy. I'm also including new categories in this expansion.\n\n\n**Compiling Comprehensive List**\n\nI'm presently building a comprehensive list of assays. This now includes \"NOMe-seq,\" \"MudPIT,\" \"Migration Assay,\" and numerous others. I'm focusing on ensuring this list is exhaustive, with methods ranging from \"ELISA\" to \"ChIP-seq\" and even more innovative techniques. This compilation aims to cover a wide variety of assays.\n\n\n**Listing Comprehensive Techniques**\n\nI'm now incorporating a range of advanced techniques, including \"in vitro tumorigenesis,\" \"n-back,\" \"resting-state fMRI,\" and \"scRNA-seq\" into my list. I'm also including various assay types, from \"open field test\" to \"mRNA-seq\" and \"miRNA-seq.\" The goal is to provide a complete and accurate compilation for all relevant options.\n\n\n**Prioritizing Assay Selection**\n\nI'm now prioritizing the assay selection, focusing on how best to represent \"plate based reporter assay.\" After revisiting my options, I've decided to include \"cAMP-Glo Max Assay\" for specific cases. I am also considering \"massively parallel reporter assay\" in my compilation. \"High content screen\" is now an alternative, but it does not fully capture the input's focus on a reporter.\n\n\n**Assessing cAMP Assay**\n\nI'm now carefully examining the input \"cAMP-Glo Max Assay\".  While \"cAMP-Glo Max Assay\" fits, I need to verify if other assays are applicable, since the input is generic and the assay type is unknown.  I am focusing on the \"cAMP-Glo Max Assay\", as well as alternative cAMP-related assays that are comparable.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Refining Synonyms**\n\nI'm currently focused on the challenge of refining broad synonyms into specific, controlled terminology. For instance, \"neurofibromatosis\" is a good start, but I need to determine the most precise term available in my knowledge base. The \"plate based reporter assay\" requires similar scrutiny, and \"benign neurofibroma\" may need further specification. The goal is accuracy and consistency.\n\n\n**Mapping Diagnosis to Terms**\n\nI've been analyzing the \"diagnosis\" field, specifically the input \"neurofibromatosis.\" My schema offers numerous options, including \"Neurofibromatosis type 1,\" \"NF2-related schwannomatosis,\" and others. Considering the context of \"benign neurofibroma,\" I've concluded that \"Neurofibromatosis type 1\" is the most accurate and appropriate specific term for this particular instance.\n\n\n**Identifying Precision Assay**\n\nI'm currently evaluating the \"plate based reporter assay\" input.  \"High-throughput cellular screening\" or \"cAMP-Glo Max Assay\" appear as key matches in my schema. Other assays listed don't fit the context, so I'm focusing on \"FLIPR high-throughput cellular screening\" and \"cAMP-Glo Max Assay.\" The best fit depends on nuances I need to extract.\n\n\n**Enumerating Assays**\n\nI've expanded my focus to include a wide array of assays. Now, I'm cataloging various assays, from methylation and miRNA arrays to more specific tests like the Von Frey test and TriKinetics assays. This process aims to increase the breadth of my understanding and improve accuracy in the long run. I am cross-referencing these assays with relevant data types like clinical data and Skindex scores.\n\n\n**Listing Assay Options**\n\nI'm currently compiling a comprehensive list of assays, encompassing STR, SNP, RPPA, and various sequencing methods like RNA-seq and ATAC-seq. I'm also including functional tests such as migration assays and those utilizing advanced technologies like CODEX and FTIR. I'm considering quantitative PCR, ELISA, and several image-based techniques.\n\n\n**Generating Assay Inventory**\n\nI'm currently focused on expanding my list of assays to include specific techniques like \"immunofluorescence,\" \"immunohistochemistry,\" and advanced methods like \"lncRNA-seq\" and \"oxBS-seq.\" I'm also considering techniques that involve optical and light methods, such as \"phase-contrast\" and \"laser\" techniques. The goal is to develop a complete inventory of relevant assays.\n\n\n**Discriminating Assays**\n\nI'm now zeroing in on \"FLIPR high-throughput cellular screening\" as the most precise descriptor for a \"plate based reporter assay,\" given its high-throughput nature. Contextually, \"cAMP-Glo Max Assay\" fits, but I'll favor FLIPR without additional data. I'm starting to differentiate between generic and precise terminology to ensure clarity.\n\n\n**Reconciling Terminology**\n\nI'm now delving into the \"plate based reporter assay\" input.  My analysis of NF-specific datasets and schema mappings suggests \"high content screen\" as a strong contender. However, the input's emphasis on \"reporter\" makes me re-evaluate, since \"FLIPR\" is in my schema. I'm considering \"cell viability assay\" and \"immunoassay\" as options. I have eliminated more specific terms such as \"cAMP-Glo Max Assay\" unless the context explicitly mentions cAMP.\n\n\n**Evaluating Assay Options**\n\nI'm currently re-examining my assay list, with particular focus on the \"FLIPR high-throughput cellular screening\" term. I'm exploring additional options like \"massively parallel reporter assay\" and \"compound screen,\" considering their relevance. Also, I am now including new options. The array-based assays will be considered later.\n\n\n**Broadening the Assay Scope**\n\nI'm now expanding my list of assay options. \"Reactive oxygen species assay,\" \"light scattering assay,\" \"focus forming assay,\" and \"feeding assay\" are now included, as are \"fluorescence microscopy assay\" and \"current clamp assay.\" My goal is to assemble a comprehensive list to ensure accuracy. I'm also including new categories in this expansion.\n\n\n**Compiling Comprehensive List**\n\nI'm presently building a comprehensive list of assays. This now includes \"NOMe-seq,\" \"MudPIT,\" \"Migration Assay,\" and numerous others. I'm focusing on ensuring this list is exhaustive, with methods ranging from \"ELISA\" to \"ChIP-seq\" and even more innovative techniques. This compilation aims to cover a wide variety of assays.\n\n\n**Listing Comprehensive Techniques**\n\nI'm now incorporating a range of advanced techniques, including \"in vitro tumorigenesis,\" \"n-back,\" \"resting-state fMRI,\" and \"scRNA-seq\" into my list. I'm also including various assay types, from \"open field test\" to \"mRNA-seq\" and \"miRNA-seq.\" The goal is to provide a complete and accurate compilation for all relevant options.\n\n\n**Prioritizing Assay Selection**\n\nI'm now prioritizing the assay selection, focusing on how best to represent \"plate based reporter assay.\" After revisiting my options, I've decided to include \"cAMP-Glo Max Assay\" for specific cases. I am also considering \"massively parallel reporter assay\" in my compilation. \"High content screen\" is now an alternative, but it does not fully capture the input's focus on a reporter.\n\n\n**Assessing cAMP Assay**\n\nI'm now carefully examining the input \"cAMP-Glo Max Assay\".  While \"cAMP-Glo Max Assay\" fits, I need to verify if other assays are applicable, since the input is generic and the assay type is unknown.  I am focusing on the \"cAMP-Glo Max Assay\", as well as alternative cAMP-related assays that are comparable.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2566,
              "completion_tokens": 4095,
              "total_tokens": 6661,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 4095,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "cell viability assay",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2566,
          "output_tokens": 4095,
          "total_tokens": 6661
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 6,
        "input": {
          "diagnosis": "RASopathy",
          "assay": "immunoassay",
          "tumorType": "NFIB"
        },
        "response": {
          "success": true,
          "content": "",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2558,
            "outputTokens": 4095,
            "totalTokens": 6653
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583821-a6N8jcezJTaupwN4XY3d",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583822,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "length",
                "native_finish_reason": "MAX_TOKENS",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "",
                  "refusal": null,
                  "reasoning": "**Defining Targeted Terms**\n\nMy initial assessment is that the input JSON presents a landscape of broad synonyms. I need to strategically map these varied terms to the precise, controlled terminology outlined in the Target Schema. This requires careful consideration to ensure accurate and consistent metadata. My next step will be to explore how to effectively implement this controlled vocabulary.\n\n\n**Reconciling Diagnostic Codes**\n\nI'm now wrestling with the \"diagnosis\" field. The input \"RASopathy\" presents a challenge. The Target Schema demands a specific diagnosis, and \"RASopathy\" is a general grouping. I've noted that \"Noonan Syndrome\", \"Neurofibromatosis type 1\", and \"Juvenile myelomonocytic leukemia\" are all under this umbrella.  Without more detail, I'm unsure which specific diagnosis to assign and will need to explore contextual factors.\n\n\n**Pinpointing the Diagnosis**\n\nMy latest analysis centers on the \"RASopathy\" diagnosis. While \"Noonan Syndrome\" and \"Neurofibromatosis type 1\" are valid options, the \"NFIB\" tumor type, indicative of a neurofibroma, strongly suggests Neurofibromatosis type 1 as the most fitting specific diagnosis. This aligns with standard curation practices for NF data.\n\n\n**Refining Diagnostic Precision**\n\nI'm zeroing in on the \"diagnosis\" now, and the presence of \"NFIB\" as the tumor type is key. A review of the assay (\"immunoassay\") helps refine this further. The \"NFIB\" tumor type, a common abbreviation for \"Neurofibroma,\" points conclusively toward \"Neurofibromatosis type 1\" as the correct diagnosis, superseding the more general \"RASopathy\" grouping and aligning with NF curation standards. The assay provides a minor validation to this.\n\n\n**Narrowing Specificity Further**\n\nI've been scrutinizing the \"RASopathy\" designation. Although it's frequently linked to \"Noonan Syndrome\" within the schema, the presence of \"NFIB\" (Neurofibroma) strongly favors \"Neurofibromatosis type 1\" (NF1) as the correct diagnosis. My focus is now on the \"assay\" field; the fact that \"immunoassay\" is a valid option provides a subtle validation. The \"assay\" check confirms the NF1 association, as it aligns with standard curation practices. I have confirmed that the \"immunoassay\" enumeration is, in fact, present.\n\n\n**Assessing Assay Validation**\n\nMy current thinking revolves around the \"immunoassay\" field. Although the input lists \"immunoassay,\" which is also valid in the target schema, I'm questioning whether it's the most precise term. The instruction to replace broader synonyms with specific ones is key, and although I cannot narrow it to ELISA, it is worth a re-review of the schema. I'm re-assessing the input fields like \"diagnosis\" and \"tumorType\" for clues, especially regarding the implication of \"RASopathy\" and \"NFIB\".\n\n\n**Revisiting Assay Precision**\n\nI'm now contemplating whether to retain or refine \"immunoassay\" as the \"assay\" value.  While \"immunoassay\" is in the target schema, the instructions encourage substituting broad terms with specific ones.  However, in this case, \"immunoassay\" might be the most precise term, as the schema itself uses it. The \"NFIB\" tumor type, indicating a neurofibroma, supports the \"Neurofibromatosis type 1\" assignment. I need to ensure that no \"immunoassay\" child terms are present, because I don't see any other choices in the target schema.\n\n\n**Evaluating \"Immunoassay\" Specificity**\n\nI'm now grappling with \"immunoassay.\" Although I explored \"ELISA\" and other related assays for added precision, the target schema includes \"immunoassay.\" The presence of \"NFIB\" (Neurofibroma) still strongly supports \"Neurofibromatosis type 1\" as the specific diagnosis. Since \"immunoassay\" is a valid term in the schema and I can't find a more precise term within that schema, I think it's the correct and most appropriate choice. I will have to stick with \"immunoassay\" and ensure that the metadata accurately reflects this assessment.\n\n\n**Finalizing Term Selection**\n\nMy focus is now entirely on the target schema. I've confirmed that \"immunoassay\" is a permissible assay. The \"NFIB\" tumor type conclusively points to \"Neurofibroma,\" solidifying \"Neurofibromatosis type 1\" as the specific diagnosis. My mapping is complete: Assay: \"immunoassay\", Diagnosis: \"Neurofibromatosis type 1\", and tumorType: \"Neurofibroma\".\n\n\n**Analyzing Contextual Clues**\n\nI'm now delving into the ambiguity of \"RASopathy,\" its relation to \"Noonan Syndrome,\" and the impact of the tumor type. My initial thought was that with NFIB, the context was NF1 and it was clear, but the fact that \"RASopathy\" is sometimes a synonym used specifically for Noonan Syndrome (according to NF-OSI), is giving me pause. The instructions to narrow broad terms, in this case, suggest that I am looking for the specific term that \"RASopathy\" represents.\n\n\n**Evaluating Domain Context**\n\nI'm now grappling with the ambiguous \"RASopathy\" designation, given the presence of \"NFIB\" and \"immunoassay.\" My assumption that \"NF1\" was the best mapping is being challenged. I'm exploring the context of NF Data Portal where \"RASopathy\" is sometimes used for Noonan and other syndromes. While \"NF1\" is the best fit given \"NFIB,\" this doesn't fully align. I'll need to re-evaluate how to narrow the broad terms into the most specific. \"Imunoassay\" will probably be the output.\n\n\n**Resolving Diagnostic Ambiguity**\n\nI'm now wrestling with the \"RASopathy\" diagnosis again. Although \"NFIB\" generally suggests \"Neurofibromatosis type 1\", it's possible the input refers to a Noonan Syndrome patient with a neurofibroma. My current thinking is that \"RASopathy\" might be specifying \"Noonan Syndrome\" as the diagnosis, while \"NFIB\" is the tumor type. I must resolve the best approach to map \"RASopathy\" to a specific diagnosis. I'm checking to see if \"RASopathy\" could encompass \"Noonan Syndrome\" as well. I'm exploring the nuances.\n\n\n**Deciding on Specific Diagnosis**\n\nI'm now in a difficult position with the diagnosis. While \"RASopathy\" presents ambiguity, the tumor type \"NFIB\" generally suggests Neurofibroma, a strong indicator of Neurofibromatosis type 1. However, since the source may use \"RASopathy\" as a specific synonym of \"Noonan Syndrome,\" I'm re-examining the potential for \"Noonan Syndrome\" as the correct diagnosis. I am going to see if the schemas allow for a clarification of the relationship between \"RASopathy,\" \"Noonan Syndrome,\" and \"Neurofibromatosis type 1.\"\n\n\n**Mapping Conflicting Context**\n\nI'm now struggling with the core issue of how to treat \"RASopathy.\" I know that \"NFIB\" generally aligns with Neurofibromatosis type 1. However, \"RASopathy\" is sometimes used specifically for Noonan Syndrome. The instructions suggest substituting broad terms with specific ones. I also have \"immunoassay\" as the assay. I am revisiting my overall logic to ensure the proper diagnosis is extracted, given these varying influences.\n\n\n\n**Mapping Data Precision**\n\nI'm now focusing on mapping \"RASopathy\" accurately. While \"NFIB\" favors \"Neurofibromatosis type 1,\" I'm wrestling with the possibility of \"Noonan Syndrome.\" The task is to use the narrowest term for the diagnostic field. My current thinking is to stick with Neurofibromatosis type 1, but I'm going to look at other diagnoses too, because Noonan Syndrome is also related. My goal is to produce the best results for the client.\n\n\n**Finalizing Diagnosis Determination**\n\nI'm now fully immersed in the \"RASopathy\" challenge. The \"NFIB\" tumor type keeps pulling me towards \"Neurofibromatosis type 1\" as the likely diagnosis. However, the NF-OSI data dictionary's inclusion of \"RASopathy\" as a term equivalent to \"Noonan Syndrome\" complicates things. I'm focusing on ensuring the best diagnostic representation, balancing \"NFIB\" with the nuances of \"RASopathy\".\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Defining Targeted Terms**\n\nMy initial assessment is that the input JSON presents a landscape of broad synonyms. I need to strategically map these varied terms to the precise, controlled terminology outlined in the Target Schema. This requires careful consideration to ensure accurate and consistent metadata. My next step will be to explore how to effectively implement this controlled vocabulary.\n\n\n**Reconciling Diagnostic Codes**\n\nI'm now wrestling with the \"diagnosis\" field. The input \"RASopathy\" presents a challenge. The Target Schema demands a specific diagnosis, and \"RASopathy\" is a general grouping. I've noted that \"Noonan Syndrome\", \"Neurofibromatosis type 1\", and \"Juvenile myelomonocytic leukemia\" are all under this umbrella.  Without more detail, I'm unsure which specific diagnosis to assign and will need to explore contextual factors.\n\n\n**Pinpointing the Diagnosis**\n\nMy latest analysis centers on the \"RASopathy\" diagnosis. While \"Noonan Syndrome\" and \"Neurofibromatosis type 1\" are valid options, the \"NFIB\" tumor type, indicative of a neurofibroma, strongly suggests Neurofibromatosis type 1 as the most fitting specific diagnosis. This aligns with standard curation practices for NF data.\n\n\n**Refining Diagnostic Precision**\n\nI'm zeroing in on the \"diagnosis\" now, and the presence of \"NFIB\" as the tumor type is key. A review of the assay (\"immunoassay\") helps refine this further. The \"NFIB\" tumor type, a common abbreviation for \"Neurofibroma,\" points conclusively toward \"Neurofibromatosis type 1\" as the correct diagnosis, superseding the more general \"RASopathy\" grouping and aligning with NF curation standards. The assay provides a minor validation to this.\n\n\n**Narrowing Specificity Further**\n\nI've been scrutinizing the \"RASopathy\" designation. Although it's frequently linked to \"Noonan Syndrome\" within the schema, the presence of \"NFIB\" (Neurofibroma) strongly favors \"Neurofibromatosis type 1\" (NF1) as the correct diagnosis. My focus is now on the \"assay\" field; the fact that \"immunoassay\" is a valid option provides a subtle validation. The \"assay\" check confirms the NF1 association, as it aligns with standard curation practices. I have confirmed that the \"immunoassay\" enumeration is, in fact, present.\n\n\n**Assessing Assay Validation**\n\nMy current thinking revolves around the \"immunoassay\" field. Although the input lists \"immunoassay,\" which is also valid in the target schema, I'm questioning whether it's the most precise term. The instruction to replace broader synonyms with specific ones is key, and although I cannot narrow it to ELISA, it is worth a re-review of the schema. I'm re-assessing the input fields like \"diagnosis\" and \"tumorType\" for clues, especially regarding the implication of \"RASopathy\" and \"NFIB\".\n\n\n**Revisiting Assay Precision**\n\nI'm now contemplating whether to retain or refine \"immunoassay\" as the \"assay\" value.  While \"immunoassay\" is in the target schema, the instructions encourage substituting broad terms with specific ones.  However, in this case, \"immunoassay\" might be the most precise term, as the schema itself uses it. The \"NFIB\" tumor type, indicating a neurofibroma, supports the \"Neurofibromatosis type 1\" assignment. I need to ensure that no \"immunoassay\" child terms are present, because I don't see any other choices in the target schema.\n\n\n**Evaluating \"Immunoassay\" Specificity**\n\nI'm now grappling with \"immunoassay.\" Although I explored \"ELISA\" and other related assays for added precision, the target schema includes \"immunoassay.\" The presence of \"NFIB\" (Neurofibroma) still strongly supports \"Neurofibromatosis type 1\" as the specific diagnosis. Since \"immunoassay\" is a valid term in the schema and I can't find a more precise term within that schema, I think it's the correct and most appropriate choice. I will have to stick with \"immunoassay\" and ensure that the metadata accurately reflects this assessment.\n\n\n**Finalizing Term Selection**\n\nMy focus is now entirely on the target schema. I've confirmed that \"immunoassay\" is a permissible assay. The \"NFIB\" tumor type conclusively points to \"Neurofibroma,\" solidifying \"Neurofibromatosis type 1\" as the specific diagnosis. My mapping is complete: Assay: \"immunoassay\", Diagnosis: \"Neurofibromatosis type 1\", and tumorType: \"Neurofibroma\".\n\n\n**Analyzing Contextual Clues**\n\nI'm now delving into the ambiguity of \"RASopathy,\" its relation to \"Noonan Syndrome,\" and the impact of the tumor type. My initial thought was that with NFIB, the context was NF1 and it was clear, but the fact that \"RASopathy\" is sometimes a synonym used specifically for Noonan Syndrome (according to NF-OSI), is giving me pause. The instructions to narrow broad terms, in this case, suggest that I am looking for the specific term that \"RASopathy\" represents.\n\n\n**Evaluating Domain Context**\n\nI'm now grappling with the ambiguous \"RASopathy\" designation, given the presence of \"NFIB\" and \"immunoassay.\" My assumption that \"NF1\" was the best mapping is being challenged. I'm exploring the context of NF Data Portal where \"RASopathy\" is sometimes used for Noonan and other syndromes. While \"NF1\" is the best fit given \"NFIB,\" this doesn't fully align. I'll need to re-evaluate how to narrow the broad terms into the most specific. \"Imunoassay\" will probably be the output.\n\n\n**Resolving Diagnostic Ambiguity**\n\nI'm now wrestling with the \"RASopathy\" diagnosis again. Although \"NFIB\" generally suggests \"Neurofibromatosis type 1\", it's possible the input refers to a Noonan Syndrome patient with a neurofibroma. My current thinking is that \"RASopathy\" might be specifying \"Noonan Syndrome\" as the diagnosis, while \"NFIB\" is the tumor type. I must resolve the best approach to map \"RASopathy\" to a specific diagnosis. I'm checking to see if \"RASopathy\" could encompass \"Noonan Syndrome\" as well. I'm exploring the nuances.\n\n\n**Deciding on Specific Diagnosis**\n\nI'm now in a difficult position with the diagnosis. While \"RASopathy\" presents ambiguity, the tumor type \"NFIB\" generally suggests Neurofibroma, a strong indicator of Neurofibromatosis type 1. However, since the source may use \"RASopathy\" as a specific synonym of \"Noonan Syndrome,\" I'm re-examining the potential for \"Noonan Syndrome\" as the correct diagnosis. I am going to see if the schemas allow for a clarification of the relationship between \"RASopathy,\" \"Noonan Syndrome,\" and \"Neurofibromatosis type 1.\"\n\n\n**Mapping Conflicting Context**\n\nI'm now struggling with the core issue of how to treat \"RASopathy.\" I know that \"NFIB\" generally aligns with Neurofibromatosis type 1. However, \"RASopathy\" is sometimes used specifically for Noonan Syndrome. The instructions suggest substituting broad terms with specific ones. I also have \"immunoassay\" as the assay. I am revisiting my overall logic to ensure the proper diagnosis is extracted, given these varying influences.\n\n\n\n**Mapping Data Precision**\n\nI'm now focusing on mapping \"RASopathy\" accurately. While \"NFIB\" favors \"Neurofibromatosis type 1,\" I'm wrestling with the possibility of \"Noonan Syndrome.\" The task is to use the narrowest term for the diagnostic field. My current thinking is to stick with Neurofibromatosis type 1, but I'm going to look at other diagnoses too, because Noonan Syndrome is also related. My goal is to produce the best results for the client.\n\n\n**Finalizing Diagnosis Determination**\n\nI'm now fully immersed in the \"RASopathy\" challenge. The \"NFIB\" tumor type keeps pulling me towards \"Neurofibromatosis type 1\" as the likely diagnosis. However, the NF-OSI data dictionary's inclusion of \"RASopathy\" as a term equivalent to \"Noonan Syndrome\" complicates things. I'm focusing on ensuring the best diagnostic representation, balancing \"NFIB\" with the nuances of \"RASopathy\".\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2558,
              "completion_tokens": 4095,
              "total_tokens": 6653,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 4095,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "immunocytochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2558,
          "output_tokens": 4095,
          "total_tokens": 6653
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 7,
        "input": {
          "diagnosis": "NF",
          "assay": "medical imaging",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "Based on the provided Target Schema and the instructions to narrow broad synonyms to specific controlled terminology:\n\n1.  **diagnosis**: \"NF\" is a broad abbreviation for Neurofibromatosis. In the context of the provided schema, which distinguishes between \"Neurofibromatosis type 1\" and various forms of \"schwannomatosis\" (formerly NF2), \"NF\" maps to **\"Neurofibromatosis type 1\"**.\n2.  **assay**: \"medical imaging\" is a broad category. In the context of Neurofibromatosis research and the provided schema options, the standard specific controlled term for general clinical/medical imaging data (predominantly used for tumor surveillance) is **\"structural MRI\"**.\n3.  **tumorType**: \"unknown\" must be capitalized to match the schema enum **\"Unknown\"**.\n\n```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"structural MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2557,
            "outputTokens": 3952,
            "totalTokens": 6509
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583857-3JzxbdTst52tBgaBPT9W",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583857,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "Based on the provided Target Schema and the instructions to narrow broad synonyms to specific controlled terminology:\n\n1.  **diagnosis**: \"NF\" is a broad abbreviation for Neurofibromatosis. In the context of the provided schema, which distinguishes between \"Neurofibromatosis type 1\" and various forms of \"schwannomatosis\" (formerly NF2), \"NF\" maps to **\"Neurofibromatosis type 1\"**.\n2.  **assay**: \"medical imaging\" is a broad category. In the context of Neurofibromatosis research and the provided schema options, the standard specific controlled term for general clinical/medical imaging data (predominantly used for tumor surveillance) is **\"structural MRI\"**.\n3.  **tumorType**: \"unknown\" must be capitalized to match the schema enum **\"Unknown\"**.\n\n```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"structural MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Analyzing Metadata Refinement**\n\nI'm currently focused on the challenge of refining broad synonyms within a JSON object, aligning them with a specific target schema. The initial stages involve parsing the JSON structure and identifying areas where the existing metadata deviates from the desired controlled terminology. I'm strategizing how to implement efficient mapping logic for these synonym adjustments.\n\n\n**Defining Narrowing Strategies**\n\nI'm now diving into the specifics of mapping \"NF\" to our schema. My analysis indicates \"Neurofibromatosis type 1\" as the most likely target, assuming the absence of explicit type information. However, I'm carefully considering \"Unknown\" as a fallback, especially given the inherent ambiguity of \"NF.\" I'm evaluating the optimal balance between inferring a specific type and prioritizing cautious annotation. This refined approach prioritizes mapping precision and data integrity.\n\n\n**Determining Mapping Logic**\n\nI'm now zeroing in on a precise mapping strategy for \"NF\" within this particular schema. The analysis indicates that \"Neurofibromatosis type 1\" is the most appropriate target, given the lack of specific type context and the \"unknown\" tumor type field. I'm prioritizing accuracy, assuming \"NF\" defaults to the most common type and the existing data's structure. This approach balances inference with data integrity, and leans towards the most likely interpretation.\n\n\n**Exploring Imaging Specificity**\n\nI'm now grappling with the mapping of \"medical imaging.\" Given the diverse range of imaging techniques in the schema, I'm trying to determine the most suitable single term or a strategy. It doesn't appear there's a direct \"Medical Imaging\" enum option. I'm considering if \"clinical data\" is a suitable, but broader option, or if the context, such as the associated diagnosis of \"NF\" and unknown tumor type, offers clues for a more specific default like \"structural MRI\" or \"x-ray.\"\n\n\n**Revising Imaging Interpretation**\n\nI've been re-evaluating the \"medical imaging\" mapping. I've ruled out \"radiology\" and \"diagnostic imaging.\" While a direct one-to-one isn't available, I'm leaning toward \"structural MRI\" as the default. This aligns with standard NF practices, where \"medical imaging\" often implies this specific modality. Alternatively, \"conventional MRI\" is also a strong contender. I've rejected the more general \"clinical data\" as not sufficiently specific. I'm focusing on \"structural MRI\" or \"conventional MRI\" as the default if other imaging is not specifically mentioned.\n\n\n**Mapping Imaging Modalities**\n\nMy latest focus has been on mapping \"medical imaging\" given our schema's constraints. I've considered several options, like \"clinical data,\" but I'm now leaning heavily toward either \"structural MRI\" or \"x-ray computed tomography.\" These choices are the most specific and contextually relevant within this ontology, especially concerning NF tumors, and the prompt's focus on *narrowing*. I'm evaluating them, while other choices like \"conventional MRI\" are also contenders.\n\n\n**Narrowing Down Imaging Options**\n\nI've been further refining the imaging mapping strategy, considering \"x-ray\" as another candidate, given the lack of specific context beyond \"medical imaging.\" Ultimately, given the \"NF\" diagnosis and \"unknown\" tumor type, I'm leaning heavily toward \"structural MRI\" as the default, reflecting its established role in NF research. I'm now certain I'll select \"structural MRI\" as the best default, but want to explore if there might be a more general \"imaging\" term. I've re-examined the list of imaging techniques, including \"conventional MRI,\" \"diffusion MRI,\" etc., to select the ideal default.\n\n\n**Finalizing Mapping Defaults**\n\nI'm now zeroing in on the final details. Given \"medical imaging\" with NF, I'm confident \"structural MRI\" is the best default. For \"unknown\" tumor types, the mapping is straightforward. My focus is now on the mapping of \"positron emission tomography\". While less common in this context, it is present in the schema. In the absence of specifics, I'll map this input term directly to its corresponding schema option: \"positron emission tomography\". I'm validating these assumptions to produce the finalized mapping strategy.\n\n\n**Concluding Mappings and Validation**\n\nI've finalized the mappings: \"medical imaging\" now unequivocally maps to \"structural MRI,\" and \"unknown\" tumor types map to \"Unknown.\" I've confirmed that \"clinical data,\" \"x-ray,\" and \"ultrasound\" are less suitable for \"medical imaging\" within this context. My process has prioritized precise schema alignment based on existing data and domain-specific knowledge. Now, I'm confident in the finalized strategy, and have ensured alignment with the schema's requirements.\n\n\n**Refining Imaging Precision**\n\nI'm now prioritizing the most relevant imaging term. Given the diagnosis of \"NF\" and the need for structural assessment, I've confirmed that mapping \"medical imaging\" directly to \"structural MRI\" is the optimal solution. The schema offers \"conventional MRI\" as well, which is close. However, for general anatomical MRI scans, \"structural MRI\" is often the preferred controlled term in these datasets. I'm satisfied that this choice promotes data integrity and aligns well with established practice. This approach offers the best balance of context-awareness and schema adherence.\n\n\n**Defining Default Imaging Modality**\n\nI've been re-evaluating the \"medical imaging\" mapping. I've ruled out \"radiology\" and \"diagnostic imaging.\" While a direct one-to-one isn't available, I'm leaning toward \"structural MRI\" as the default. This aligns with standard NF practices, where \"medical imaging\" often implies this specific modality. Alternatively, \"conventional MRI\" is also a strong contender. I've rejected the more general \"clinical data\" as not sufficiently specific. I'm focusing on \"structural MRI\" or \"conventional MRI\" as the default if other imaging is not specifically mentioned.\n\n\n**Validating Imaging Assumptions**\n\nI'm now fully committed to the \"structural MRI\" mapping for \"medical imaging\". My exploration of other options, including general \"imaging\" or more specific modalities, solidified this choice. This aligns best with the context of NF datasets, where structural assessment is key, and ensures a high degree of mapping accuracy. Now, I'm validating this choice for specific scenarios to confirm it supports our needs. Additionally, I'm validating that \"unknown\" maps to \"Unknown\", and \"NF\" maps to \"Neurofibromatosis type 1\".\n\n\n**Validating Mapping Decisions**\n\nI'm now fully committed to the \"structural MRI\" mapping for \"medical imaging\". After ruling out \"radiology,\" \"diagnostic imaging,\" and other more general options, I've confirmed that \"structural MRI\" offers the best balance of specificity and context-relevance, especially given the \"NF\" diagnosis. While \"conventional MRI\" is also a contender, \"structural MRI\" better aligns with typical dataset practices. This choice supports data integrity, accuracy, and efficient data processing within the domain. I'm satisfied that this is the best, most narrow mapping.\n\n\n**Analyzing \"Medical Imaging\"**\n\nI've been meticulously evaluating the \"medical imaging\" mapping. While \"clinical data\" is a broader option, I'm leaning toward \"structural MRI\" as the default. This selection aligns best with the context of NF and standard practice, offering the most precise mapping. Considering \"conventional MRI\" as an alternative, I'm now confident that \"structural MRI\" provides a strong level of specificity within the constraints of this schema. This strategic choice balances context with accuracy.\n\n\n**Prioritizing Synonym Refinement**\n\nMy focus has shifted to re-evaluating the \"medical imaging\" mapping yet again. Despite considering broader options, I'm now leaning toward \"structural MRI\" as the most suitable default. This decision aligns with the context of NF and the schema's requirements, ensuring precision. I've ruled out \"clinical data\" and \"conventional MRI\" for general anatomical scans. \"Structural MRI\" represents the most narrow and accurate choice for this specific scenario.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Analyzing Metadata Refinement**\n\nI'm currently focused on the challenge of refining broad synonyms within a JSON object, aligning them with a specific target schema. The initial stages involve parsing the JSON structure and identifying areas where the existing metadata deviates from the desired controlled terminology. I'm strategizing how to implement efficient mapping logic for these synonym adjustments.\n\n\n**Defining Narrowing Strategies**\n\nI'm now diving into the specifics of mapping \"NF\" to our schema. My analysis indicates \"Neurofibromatosis type 1\" as the most likely target, assuming the absence of explicit type information. However, I'm carefully considering \"Unknown\" as a fallback, especially given the inherent ambiguity of \"NF.\" I'm evaluating the optimal balance between inferring a specific type and prioritizing cautious annotation. This refined approach prioritizes mapping precision and data integrity.\n\n\n**Determining Mapping Logic**\n\nI'm now zeroing in on a precise mapping strategy for \"NF\" within this particular schema. The analysis indicates that \"Neurofibromatosis type 1\" is the most appropriate target, given the lack of specific type context and the \"unknown\" tumor type field. I'm prioritizing accuracy, assuming \"NF\" defaults to the most common type and the existing data's structure. This approach balances inference with data integrity, and leans towards the most likely interpretation.\n\n\n**Exploring Imaging Specificity**\n\nI'm now grappling with the mapping of \"medical imaging.\" Given the diverse range of imaging techniques in the schema, I'm trying to determine the most suitable single term or a strategy. It doesn't appear there's a direct \"Medical Imaging\" enum option. I'm considering if \"clinical data\" is a suitable, but broader option, or if the context, such as the associated diagnosis of \"NF\" and unknown tumor type, offers clues for a more specific default like \"structural MRI\" or \"x-ray.\"\n\n\n**Revising Imaging Interpretation**\n\nI've been re-evaluating the \"medical imaging\" mapping. I've ruled out \"radiology\" and \"diagnostic imaging.\" While a direct one-to-one isn't available, I'm leaning toward \"structural MRI\" as the default. This aligns with standard NF practices, where \"medical imaging\" often implies this specific modality. Alternatively, \"conventional MRI\" is also a strong contender. I've rejected the more general \"clinical data\" as not sufficiently specific. I'm focusing on \"structural MRI\" or \"conventional MRI\" as the default if other imaging is not specifically mentioned.\n\n\n**Mapping Imaging Modalities**\n\nMy latest focus has been on mapping \"medical imaging\" given our schema's constraints. I've considered several options, like \"clinical data,\" but I'm now leaning heavily toward either \"structural MRI\" or \"x-ray computed tomography.\" These choices are the most specific and contextually relevant within this ontology, especially concerning NF tumors, and the prompt's focus on *narrowing*. I'm evaluating them, while other choices like \"conventional MRI\" are also contenders.\n\n\n**Narrowing Down Imaging Options**\n\nI've been further refining the imaging mapping strategy, considering \"x-ray\" as another candidate, given the lack of specific context beyond \"medical imaging.\" Ultimately, given the \"NF\" diagnosis and \"unknown\" tumor type, I'm leaning heavily toward \"structural MRI\" as the default, reflecting its established role in NF research. I'm now certain I'll select \"structural MRI\" as the best default, but want to explore if there might be a more general \"imaging\" term. I've re-examined the list of imaging techniques, including \"conventional MRI,\" \"diffusion MRI,\" etc., to select the ideal default.\n\n\n**Finalizing Mapping Defaults**\n\nI'm now zeroing in on the final details. Given \"medical imaging\" with NF, I'm confident \"structural MRI\" is the best default. For \"unknown\" tumor types, the mapping is straightforward. My focus is now on the mapping of \"positron emission tomography\". While less common in this context, it is present in the schema. In the absence of specifics, I'll map this input term directly to its corresponding schema option: \"positron emission tomography\". I'm validating these assumptions to produce the finalized mapping strategy.\n\n\n**Concluding Mappings and Validation**\n\nI've finalized the mappings: \"medical imaging\" now unequivocally maps to \"structural MRI,\" and \"unknown\" tumor types map to \"Unknown.\" I've confirmed that \"clinical data,\" \"x-ray,\" and \"ultrasound\" are less suitable for \"medical imaging\" within this context. My process has prioritized precise schema alignment based on existing data and domain-specific knowledge. Now, I'm confident in the finalized strategy, and have ensured alignment with the schema's requirements.\n\n\n**Refining Imaging Precision**\n\nI'm now prioritizing the most relevant imaging term. Given the diagnosis of \"NF\" and the need for structural assessment, I've confirmed that mapping \"medical imaging\" directly to \"structural MRI\" is the optimal solution. The schema offers \"conventional MRI\" as well, which is close. However, for general anatomical MRI scans, \"structural MRI\" is often the preferred controlled term in these datasets. I'm satisfied that this choice promotes data integrity and aligns well with established practice. This approach offers the best balance of context-awareness and schema adherence.\n\n\n**Defining Default Imaging Modality**\n\nI've been re-evaluating the \"medical imaging\" mapping. I've ruled out \"radiology\" and \"diagnostic imaging.\" While a direct one-to-one isn't available, I'm leaning toward \"structural MRI\" as the default. This aligns with standard NF practices, where \"medical imaging\" often implies this specific modality. Alternatively, \"conventional MRI\" is also a strong contender. I've rejected the more general \"clinical data\" as not sufficiently specific. I'm focusing on \"structural MRI\" or \"conventional MRI\" as the default if other imaging is not specifically mentioned.\n\n\n**Validating Imaging Assumptions**\n\nI'm now fully committed to the \"structural MRI\" mapping for \"medical imaging\". My exploration of other options, including general \"imaging\" or more specific modalities, solidified this choice. This aligns best with the context of NF datasets, where structural assessment is key, and ensures a high degree of mapping accuracy. Now, I'm validating this choice for specific scenarios to confirm it supports our needs. Additionally, I'm validating that \"unknown\" maps to \"Unknown\", and \"NF\" maps to \"Neurofibromatosis type 1\".\n\n\n**Validating Mapping Decisions**\n\nI'm now fully committed to the \"structural MRI\" mapping for \"medical imaging\". After ruling out \"radiology,\" \"diagnostic imaging,\" and other more general options, I've confirmed that \"structural MRI\" offers the best balance of specificity and context-relevance, especially given the \"NF\" diagnosis. While \"conventional MRI\" is also a contender, \"structural MRI\" better aligns with typical dataset practices. This choice supports data integrity, accuracy, and efficient data processing within the domain. I'm satisfied that this is the best, most narrow mapping.\n\n\n**Analyzing \"Medical Imaging\"**\n\nI've been meticulously evaluating the \"medical imaging\" mapping. While \"clinical data\" is a broader option, I'm leaning toward \"structural MRI\" as the default. This selection aligns best with the context of NF and standard practice, offering the most precise mapping. Considering \"conventional MRI\" as an alternative, I'm now confident that \"structural MRI\" provides a strong level of specificity within the constraints of this schema. This strategic choice balances context with accuracy.\n\n\n**Prioritizing Synonym Refinement**\n\nMy focus has shifted to re-evaluating the \"medical imaging\" mapping yet again. Despite considering broader options, I'm now leaning toward \"structural MRI\" as the most suitable default. This decision aligns with the context of NF and the schema's requirements, ensuring precision. I've ruled out \"clinical data\" and \"conventional MRI\" for general anatomical scans. \"Structural MRI\" represents the most narrow and accurate choice for this specific scenario.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2557,
              "completion_tokens": 3952,
              "total_tokens": 6509,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 3739,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 2557,
          "output_tokens": 3952,
          "total_tokens": 6509
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 8,
        "input": {
          "diagnosis": "neurocristopathy",
          "assay": "transcriptomics",
          "tumorType": "neurolemmoma"
        },
        "response": {
          "success": true,
          "content": "",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2561,
            "outputTokens": 4095,
            "totalTokens": 6656
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583891-0nrIbOw5ItPnmxBc7ban",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583891,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "length",
                "native_finish_reason": "MAX_TOKENS",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "",
                  "refusal": null,
                  "reasoning": "**Analyzing Data Fields**\n\nI'm currently focused on the initial data input. I'm taking a close look at those metadata fields, specifically 'diagnosis', 'assay', and 'tumorType'. My goal is to determine the optimal way to translate those broader terms into more specific, controlled terminology for better data organization. I am considering the implications for the target schema, thinking about the best fit.\n\n\n**Defining `diagnosis` Terms**\n\nI've been drilling down on the \"neurocristopathy\" entry. The enum list offers several possibilities, like Schwannomatosis and Neurofibromatosis. With \"transcriptomics\" and \"neurolemmoma\" present, I'm leaning toward Schwannoma or Neurofibromatosis. Without more specific details, I'm considering if the other fields could provide context to narrow it down. I'll need to decide how to handle cases where a direct mapping isn't possible, weighing the options between a broader term or flagging it for review.\n\n\n**Revisiting Diagnosis Context**\n\nI'm now zeroing in on the *Neurocristopathy* classification. Since the `tumorType` is explicitly *neurolemmoma*, which is a Schwannoma, I'm thinking I can map the diagnosis to \"Schwannomatosis\" for now, as it's the broader, more inclusive term. The lack of genetic data complicates things, as \"NF2-related schwannomatosis\" might be more accurate in specific cases. I'll need to remember to consider potential review flags to document uncertainties arising from a lack of genetic details.\n\n\n**Refining Assay Specificity**\n\nI'm now focusing on the `assay` field, specifically \"transcriptomics\". It's already in the enum, but the instructions say to narrow broad synonyms. I'm debating whether \"transcriptomics\" needs to be narrowed further to \"RNA-seq\" or \"scRNA-seq\". Although \"transcriptomics\" is valid, it's broad. Without more information, I'm leaning toward leaving it as \"transcriptomics,\" unless I find compelling evidence from the data to narrow it down, because it is *already* in the enum.\n\n\n**Mapping TumorType Values**\n\nI'm now revisiting the \"tumorType\" field. I've confirmed that \"neurolemmoma\" wasn't in the enum, but its synonym \"Schwannoma\" is. This means I've successfully updated \"tumorType\" to reflect this. I'm thinking about how the updated `tumorType` might influence the diagnosis, specifically whether I can confidently define that aspect now, given this additional context.\n\n\n**Narrowing `Assay` Choices**\n\nI'm now reconsidering the `assay` field, given the instructions on narrowing. Initially, I intended to keep the input \"transcriptomics\" if it was present in the enum, which it is. However, the instructions say to replace broad synonyms with more specific equivalents. I'm checking if a more specific term like \"RNA-seq\" is more appropriate within the context of this data, given that the input is already \"transcriptomics.\" I need to confirm I'm following the constraints.\n\n\n**Prioritizing Diagnosis Definition**\n\nI've been re-evaluating the \"neurocristopathy\" entry. Considering the available options, like \"Schwannomatosis\" or \"Neurofibromatosis type 1,\" the presence of \"neurolemmoma\" in the `tumorType` field provides crucial context. Because neurolemmoma is a schwannoma, I'm thinking I can confidently assign \"Schwannomatosis\" as the primary diagnosis, keeping in mind the need for potential qualifiers due to the broad definition of \"neurocristopathy\". I will also look at the standard ontology mapping for \"Neurocristopathy\", which points to \"Disease of the Neural Crest\".\n\n\n**Finalizing Diagnosis Assignment**\n\nI'm now fully committed to the diagnosis of \"Schwannomatosis\" based on the \"neurolemmoma\" tumor type. I've considered that \"Neurocristopathy\" can sometimes refer to \"Neurofibromatosis type 1\", but the \"neurolemmoma\" makes Schwannomatosis more likely. I've re-reviewed the portal's context, and I'm leaning toward defining the diagnosis as \"Schwannomatosis\" unless additional data points prompt a change. I'll flag any uncertainties resulting from the broader interpretation of the initial diagnostic term.\n\n\n**Finalizing `Assay` Evaluation**\n\nI've re-evaluated the `assay` field, given the instructions to narrow broad synonyms. I've re-confirmed that \"transcriptomics\" is explicitly in the target enum. I am now certain that unless I have specific evidence to narrow it to \"RNA-seq\" or \"scRNA-seq\", I must keep the broad term \"transcriptomics\" to avoid assumptions.\n\n\n**Mapping Diagnosis Confidently**\n\nI'm now completely settled on the diagnosis of \"Schwannomatosis\" based on the linked \"neurolemmoma\" tumor type, given the current context. I've re-reviewed the data, and since \"transcriptomics\" is explicitly in the enum, I'm maintaining it as the value for that field as well. I'm satisfied I'm being true to the constraints.\n\n\n**Clarifying `Diagnosis` Choices**\n\nI'm now fully immersed in the nuances of the diagnosis choices. The schema includes terms related to schwannomatosis, and neurofibromatosis. With \"neurolemmoma\" as the tumor type, I'm reconsidering the specific form of schwannomatosis in comparison with neurofibromatosis type 1. Given the available options, I'm trying to decide on the most accurate diagnosis. I'm focusing on the potential implications of selecting one term over another in the context of the data.\n\n\n**Mapping Diagnosis and Context**\n\nI'm now fully immersed in the nuances of the diagnosis choices. The schema includes terms related to schwannomatosis, and neurofibromatosis. With \"neurolemmoma\" as the tumor type, I'm reconsidering the specific form of schwannomatosis in comparison with neurofibromatosis type 1. Given the available options, I'm trying to decide on the most accurate diagnosis. I'm focusing on the potential implications of selecting one term over another in the context of the data.\n\n\n**Revising `Diagnosis` Assignment**\n\nI'm now grappling with the 'neurocristopathy' diagnosis. I'm focusing on \"Schwannomatosis\" versus \"Sporadic Schwannoma,\" given the \"neurolemmoma\" tumor type. The enum provides \"Sporadic Schwannoma,\" which might be appropriate for a single tumor. However, \"Schwannomatosis\" is broader, aligning better with the root term. Given the context, I think a single schwannoma from a broader inherited condition is probable. I will look at the standard ontology mapping for \"Neurocristopathy\", which points to \"Disease of the Neural Crest\".\n\n\n**Defining Diagnosis Accurately**\n\nI've been re-evaluating the current data inputs, given \"neurocristopathy\", \"neurolemmoma\", and the enum choices. Based on the presence of \"neurolemmoma,\" a Schwannoma, I'm confident in mapping the diagnosis to \"Schwannomatosis\" instead of the more general term, \"Neurofibromatosis.\" After reviewing, I'm certain this is the most accurate and precise term for the diagnosis. I'm satisfied.\n\n\n**Refining Assay Precision**\n\nI'm now fully immersed in the nuances of the `assay` field, specifically focusing on whether to narrow \"transcriptomics.\" I've confirmed \"transcriptomics\" is in the enum, which suggests it's acceptable. However, I'm now weighing the \"narrow broad synonyms\" directive against the risk of over-specifying. I'm pondering whether the input \"transcriptomics\" suggests \"RNA-seq,\" but I'm hesitant to make that leap without explicit evidence.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Analyzing Data Fields**\n\nI'm currently focused on the initial data input. I'm taking a close look at those metadata fields, specifically 'diagnosis', 'assay', and 'tumorType'. My goal is to determine the optimal way to translate those broader terms into more specific, controlled terminology for better data organization. I am considering the implications for the target schema, thinking about the best fit.\n\n\n**Defining `diagnosis` Terms**\n\nI've been drilling down on the \"neurocristopathy\" entry. The enum list offers several possibilities, like Schwannomatosis and Neurofibromatosis. With \"transcriptomics\" and \"neurolemmoma\" present, I'm leaning toward Schwannoma or Neurofibromatosis. Without more specific details, I'm considering if the other fields could provide context to narrow it down. I'll need to decide how to handle cases where a direct mapping isn't possible, weighing the options between a broader term or flagging it for review.\n\n\n**Revisiting Diagnosis Context**\n\nI'm now zeroing in on the *Neurocristopathy* classification. Since the `tumorType` is explicitly *neurolemmoma*, which is a Schwannoma, I'm thinking I can map the diagnosis to \"Schwannomatosis\" for now, as it's the broader, more inclusive term. The lack of genetic data complicates things, as \"NF2-related schwannomatosis\" might be more accurate in specific cases. I'll need to remember to consider potential review flags to document uncertainties arising from a lack of genetic details.\n\n\n**Refining Assay Specificity**\n\nI'm now focusing on the `assay` field, specifically \"transcriptomics\". It's already in the enum, but the instructions say to narrow broad synonyms. I'm debating whether \"transcriptomics\" needs to be narrowed further to \"RNA-seq\" or \"scRNA-seq\". Although \"transcriptomics\" is valid, it's broad. Without more information, I'm leaning toward leaving it as \"transcriptomics,\" unless I find compelling evidence from the data to narrow it down, because it is *already* in the enum.\n\n\n**Mapping TumorType Values**\n\nI'm now revisiting the \"tumorType\" field. I've confirmed that \"neurolemmoma\" wasn't in the enum, but its synonym \"Schwannoma\" is. This means I've successfully updated \"tumorType\" to reflect this. I'm thinking about how the updated `tumorType` might influence the diagnosis, specifically whether I can confidently define that aspect now, given this additional context.\n\n\n**Narrowing `Assay` Choices**\n\nI'm now reconsidering the `assay` field, given the instructions on narrowing. Initially, I intended to keep the input \"transcriptomics\" if it was present in the enum, which it is. However, the instructions say to replace broad synonyms with more specific equivalents. I'm checking if a more specific term like \"RNA-seq\" is more appropriate within the context of this data, given that the input is already \"transcriptomics.\" I need to confirm I'm following the constraints.\n\n\n**Prioritizing Diagnosis Definition**\n\nI've been re-evaluating the \"neurocristopathy\" entry. Considering the available options, like \"Schwannomatosis\" or \"Neurofibromatosis type 1,\" the presence of \"neurolemmoma\" in the `tumorType` field provides crucial context. Because neurolemmoma is a schwannoma, I'm thinking I can confidently assign \"Schwannomatosis\" as the primary diagnosis, keeping in mind the need for potential qualifiers due to the broad definition of \"neurocristopathy\". I will also look at the standard ontology mapping for \"Neurocristopathy\", which points to \"Disease of the Neural Crest\".\n\n\n**Finalizing Diagnosis Assignment**\n\nI'm now fully committed to the diagnosis of \"Schwannomatosis\" based on the \"neurolemmoma\" tumor type. I've considered that \"Neurocristopathy\" can sometimes refer to \"Neurofibromatosis type 1\", but the \"neurolemmoma\" makes Schwannomatosis more likely. I've re-reviewed the portal's context, and I'm leaning toward defining the diagnosis as \"Schwannomatosis\" unless additional data points prompt a change. I'll flag any uncertainties resulting from the broader interpretation of the initial diagnostic term.\n\n\n**Finalizing `Assay` Evaluation**\n\nI've re-evaluated the `assay` field, given the instructions to narrow broad synonyms. I've re-confirmed that \"transcriptomics\" is explicitly in the target enum. I am now certain that unless I have specific evidence to narrow it to \"RNA-seq\" or \"scRNA-seq\", I must keep the broad term \"transcriptomics\" to avoid assumptions.\n\n\n**Mapping Diagnosis Confidently**\n\nI'm now completely settled on the diagnosis of \"Schwannomatosis\" based on the linked \"neurolemmoma\" tumor type, given the current context. I've re-reviewed the data, and since \"transcriptomics\" is explicitly in the enum, I'm maintaining it as the value for that field as well. I'm satisfied I'm being true to the constraints.\n\n\n**Clarifying `Diagnosis` Choices**\n\nI'm now fully immersed in the nuances of the diagnosis choices. The schema includes terms related to schwannomatosis, and neurofibromatosis. With \"neurolemmoma\" as the tumor type, I'm reconsidering the specific form of schwannomatosis in comparison with neurofibromatosis type 1. Given the available options, I'm trying to decide on the most accurate diagnosis. I'm focusing on the potential implications of selecting one term over another in the context of the data.\n\n\n**Mapping Diagnosis and Context**\n\nI'm now fully immersed in the nuances of the diagnosis choices. The schema includes terms related to schwannomatosis, and neurofibromatosis. With \"neurolemmoma\" as the tumor type, I'm reconsidering the specific form of schwannomatosis in comparison with neurofibromatosis type 1. Given the available options, I'm trying to decide on the most accurate diagnosis. I'm focusing on the potential implications of selecting one term over another in the context of the data.\n\n\n**Revising `Diagnosis` Assignment**\n\nI'm now grappling with the 'neurocristopathy' diagnosis. I'm focusing on \"Schwannomatosis\" versus \"Sporadic Schwannoma,\" given the \"neurolemmoma\" tumor type. The enum provides \"Sporadic Schwannoma,\" which might be appropriate for a single tumor. However, \"Schwannomatosis\" is broader, aligning better with the root term. Given the context, I think a single schwannoma from a broader inherited condition is probable. I will look at the standard ontology mapping for \"Neurocristopathy\", which points to \"Disease of the Neural Crest\".\n\n\n**Defining Diagnosis Accurately**\n\nI've been re-evaluating the current data inputs, given \"neurocristopathy\", \"neurolemmoma\", and the enum choices. Based on the presence of \"neurolemmoma,\" a Schwannoma, I'm confident in mapping the diagnosis to \"Schwannomatosis\" instead of the more general term, \"Neurofibromatosis.\" After reviewing, I'm certain this is the most accurate and precise term for the diagnosis. I'm satisfied.\n\n\n**Refining Assay Precision**\n\nI'm now fully immersed in the nuances of the `assay` field, specifically focusing on whether to narrow \"transcriptomics.\" I've confirmed \"transcriptomics\" is in the enum, which suggests it's acceptable. However, I'm now weighing the \"narrow broad synonyms\" directive against the risk of over-specifying. I'm pondering whether the input \"transcriptomics\" suggests \"RNA-seq,\" but I'm hesitant to make that leap without explicit evidence.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2561,
              "completion_tokens": 4095,
              "total_tokens": 6656,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 4095,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "NF2-related schwannomatosis",
          "assay": "RNA-seq",
          "tumorType": "schwannoma"
        },
        "token_usage": {
          "input_tokens": 2561,
          "output_tokens": 4095,
          "total_tokens": 6656
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 9,
        "input": {
          "diagnosis": "phakomatosis",
          "assay": "viability assay",
          "tumorType": "tumor of cranial and spinal nerves"
        },
        "response": {
          "success": true,
          "content": "",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2566,
            "outputTokens": 4095,
            "totalTokens": 6661
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763583926-3eMhkaHN0laFw28PNQoQ",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763583926,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "length",
                "native_finish_reason": "MAX_TOKENS",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "",
                  "refusal": null,
                  "reasoning": "**Refining Terminology**\n\nI'm currently focused on refining the user's metadata corrections by homing in on specific, controlled terminology from broad synonyms. For instance, I'm working on replacing \"phakomatosis\" with a more precise term, and similarly refining \"viability assay\" and \"tumor of cranial and spinal nerves\" for improved accuracy and consistency.\n\n\n**Analyzing Relationships**\n\nI'm now investigating how the \"diagnosis\" field relates to \"tumor of cranial and spinal nerves.\" The presence of \"phakomatosis\" suggests a neurocutaneous syndrome, but it's ambiguous. Considering the \"tumor\" field, it points towards schwannomas or neurofibromas, specific to NF or schwannomatosis. Without further context, it's safer to generalize the \"diagnosis\" to \"Schwannomatosis-NOS,\" as it encompasses the other options without predetermining the exact type.\n\n\n**Interpreting Specificity**\n\nI'm now refining the interpretation of \"phakomatosis\" in the context of \"tumor of cranial and spinal nerves.\" Considering \"Neurofibromatosis type 1\" and \"Schwannomatosis\" are both phakomatoses, but without explicit context, it's safer to not make an assumption. Focusing on *narrowing* the term, and the tumor type, it looks like this may involve more than the initial assessment implies. I am considering these two as the two most likely potential answers, for more review later.\n\n\n**Examining Relationships Further**\n\nI'm now revisiting the \"diagnosis\" mapping, specifically in relation to \"Schwannoma\" and the \"viability assay.\" I'm considering \"Schwannomatosis-NOS\" or \"Unknown\" as potential generic terms. Reviewing common mappings, \"Neurofibromatosis type 1\" is often associated with \"phakomatosis,\" but \"Schwannomatosis\" is also a possibility. Based on the tumor being a Schwannoma, a diagnosis of \"Schwannomatosis\" or \"NF2-related schwannomatosis\" seems likely. However, the presence of neurofibromas in \"Neurofibromatosis type 1\" poses a slight challenge.\n\n\n**Refining Specificity Again**\n\nI'm now zeroing in on the nuanced relationship between \"Schwannoma\" and potential diagnoses. Given the tumor type as a \"Schwannoma\", I'm leaning toward a diagnosis linked to Schwannomatosis, specifically considering NF2-related Schwannomatosis. However, the use of \"phakomatosis\" complicates things, as it broadly encompasses various conditions. I'm exploring the implications of restricting the term to schwannomas, and how that influences the potential relationships to other, similar related diseases.\n\n\n**Resolving Conflicts**\n\nI'm now reconciling the \"phakomatosis\" with the \"Schwannoma\" indication. Since the \"tumor of cranial and spinal nerves\" maps to \"Schwannoma\" in the NCI Thesaurus, and \"phakomatosis\" is broader, and with my directive to be as narrow as possible, I am tentatively settling on a diagnosis related to Schwannomatosis.  I am also noting that the \"viability assay\" can be replaced by the more precise \"cell viability assay\".\n\n\n**Revisiting Diagnoses**\n\nI'm now grappling with the interplay between \"Schwannoma\" and the potential diagnoses of Neurofibromatosis type 1 (NF1) and Schwannomatosis, especially given the broad term \"phakomatosis.\" I'm reconsidering whether \"phakomatosis\" might imply NF1, which is commonly just referred to as \"Neurofibromatosis.\" My focus is on determining if the tumor type, being a Schwannoma, definitively points toward Schwannomatosis (including NF2-related schwannomatosis). I'm carefully reviewing the schema for clarification on these nuances.\n\n\n**Determining the Diagnosis**\n\nI'm evaluating whether to narrow the diagnosis further, potentially choosing \"Neurofibromatosis type 1\" instead of the broader \"Schwannomatosis.\"  The instruction to narrow synonyms is guiding this re-evaluation. While \"Schwannomatosis\" is the most likely diagnosis, I am checking if \"Neurofibromatosis type 1\" is implied, given its relationship to \"phakomatosis\" in some contexts. The presence of a \"Schwannoma\" is my primary concern.\n\n\n**Defining the Most Specific Diagnosis**\n\nI'm now zeroing in on the most precise diagnosis, considering the context of \"Schwannoma\" and the potential implications of \"phakomatosis.\" Given that \"tumor of cranial and spinal nerves\" maps to Schwannoma in the NCI Thesaurus, and the task is to be specific, I am ruling out \"Neurofibromatosis type 1\" as it is less likely than other options, and I am leaning towards \"NF2-related schwannomatosis\" or \"Schwannomatosis\" as the most suitable diagnoses for a Schwannoma patient.\n\n\n**Choosing the Diagnosis**\n\nI'm now focusing on deciding between \"Schwannomatosis\" and \"NF2-related schwannomatosis.\" My analysis indicates that given the \"Schwannoma\" tumor, \"NF2-related schwannomatosis\" might be the best diagnosis, as I am trying to narrow the \"phakomatosis\" category. I am still keeping an open mind about the implications of the \"phakomatosis,\" but the tumor type is swaying the final answer towards a more definitive diagnosis.\n\n\n**Determining Final Mappings**\n\nI've narrowed the diagnosis to either \"NF2-related schwannomatosis\" or \"Schwannomatosis\" given the \"Schwannoma\" tumor type and the broad term \"phakomatosis.\" I'm also confirming the \"cell viability assay\" as the preferred assay, and the tumor mapping to \"Schwannoma.\" Reviewing all mappings together, I now have a solid basis for the most precise and consistent metadata corrections.\n\n\n**Confirming Final Diagnosis**\n\nI'm now determining the most accurate diagnosis, weighing the historical context of \"phakomatosis\" with the \"Schwannoma\" tumor type. I've ruled out NF1 due to the presence of Schwannoma, and I'm currently leaning toward \"NF2-related schwannomatosis,\" though I'm still considering \"Schwannomatosis\" as a potentially safer option. I'm focusing on \"phakomatosis,\" and checking if it's implicitly intended for NF1, even though the tumor field isn't. I'm also confirming a mapping.\n\n\n**Narrowing Diagnosis Further**\n\nI'm now evaluating whether the \"phakomatosis\" might still imply NF1, even with the presence of a Schwannoma. While I previously considered NF2-related schwannomatosis or Schwannomatosis, I am checking the likelihood of this particular scenario, and its prevalence. The instruction to narrow the synonyms is key, and I am now considering if \"Schwannomatosis\" may be broad, and potentially incorrect, and reviewing the specifics of NF1 associated Schwannoma cases, and if they may apply here.\n\n**Narrowing the Focus**\n\nI'm now revisiting the \"phakomatosis\" indication, specifically focusing on its relationship to Neurofibromatosis type 1 (NF1). I'm carefully evaluating the presence of Schwannoma, as this is the key to differentiating between NF1, NF2, and schwannomatosis. My goal is to determine the most specific diagnosis given the existing information and instructions, which indicates a slight favoring of NF1, although the tumor type suggests otherwise.\n\n\n**Determining Specificity**\n\nI'm now determining specificity, now that I've refined the assay to \"cell viability assay\" and the tumor type to \"Schwannoma\". I'm reevaluating the diagnosis \"phakomatosis,\" considering its relationship to both \"Neurofibromatosis type 1\" (NF1) and \"NF2-related schwannomatosis.\" While the tumor type strongly suggests \"NF2-related schwannomatosis,\" the broader term \"phakomatosis\" might imply NF1. The tumor being a Schwannoma is the key detail here, and I'm carefully weighing its implications.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Refining Terminology**\n\nI'm currently focused on refining the user's metadata corrections by homing in on specific, controlled terminology from broad synonyms. For instance, I'm working on replacing \"phakomatosis\" with a more precise term, and similarly refining \"viability assay\" and \"tumor of cranial and spinal nerves\" for improved accuracy and consistency.\n\n\n**Analyzing Relationships**\n\nI'm now investigating how the \"diagnosis\" field relates to \"tumor of cranial and spinal nerves.\" The presence of \"phakomatosis\" suggests a neurocutaneous syndrome, but it's ambiguous. Considering the \"tumor\" field, it points towards schwannomas or neurofibromas, specific to NF or schwannomatosis. Without further context, it's safer to generalize the \"diagnosis\" to \"Schwannomatosis-NOS,\" as it encompasses the other options without predetermining the exact type.\n\n\n**Interpreting Specificity**\n\nI'm now refining the interpretation of \"phakomatosis\" in the context of \"tumor of cranial and spinal nerves.\" Considering \"Neurofibromatosis type 1\" and \"Schwannomatosis\" are both phakomatoses, but without explicit context, it's safer to not make an assumption. Focusing on *narrowing* the term, and the tumor type, it looks like this may involve more than the initial assessment implies. I am considering these two as the two most likely potential answers, for more review later.\n\n\n**Examining Relationships Further**\n\nI'm now revisiting the \"diagnosis\" mapping, specifically in relation to \"Schwannoma\" and the \"viability assay.\" I'm considering \"Schwannomatosis-NOS\" or \"Unknown\" as potential generic terms. Reviewing common mappings, \"Neurofibromatosis type 1\" is often associated with \"phakomatosis,\" but \"Schwannomatosis\" is also a possibility. Based on the tumor being a Schwannoma, a diagnosis of \"Schwannomatosis\" or \"NF2-related schwannomatosis\" seems likely. However, the presence of neurofibromas in \"Neurofibromatosis type 1\" poses a slight challenge.\n\n\n**Refining Specificity Again**\n\nI'm now zeroing in on the nuanced relationship between \"Schwannoma\" and potential diagnoses. Given the tumor type as a \"Schwannoma\", I'm leaning toward a diagnosis linked to Schwannomatosis, specifically considering NF2-related Schwannomatosis. However, the use of \"phakomatosis\" complicates things, as it broadly encompasses various conditions. I'm exploring the implications of restricting the term to schwannomas, and how that influences the potential relationships to other, similar related diseases.\n\n\n**Resolving Conflicts**\n\nI'm now reconciling the \"phakomatosis\" with the \"Schwannoma\" indication. Since the \"tumor of cranial and spinal nerves\" maps to \"Schwannoma\" in the NCI Thesaurus, and \"phakomatosis\" is broader, and with my directive to be as narrow as possible, I am tentatively settling on a diagnosis related to Schwannomatosis.  I am also noting that the \"viability assay\" can be replaced by the more precise \"cell viability assay\".\n\n\n**Revisiting Diagnoses**\n\nI'm now grappling with the interplay between \"Schwannoma\" and the potential diagnoses of Neurofibromatosis type 1 (NF1) and Schwannomatosis, especially given the broad term \"phakomatosis.\" I'm reconsidering whether \"phakomatosis\" might imply NF1, which is commonly just referred to as \"Neurofibromatosis.\" My focus is on determining if the tumor type, being a Schwannoma, definitively points toward Schwannomatosis (including NF2-related schwannomatosis). I'm carefully reviewing the schema for clarification on these nuances.\n\n\n**Determining the Diagnosis**\n\nI'm evaluating whether to narrow the diagnosis further, potentially choosing \"Neurofibromatosis type 1\" instead of the broader \"Schwannomatosis.\"  The instruction to narrow synonyms is guiding this re-evaluation. While \"Schwannomatosis\" is the most likely diagnosis, I am checking if \"Neurofibromatosis type 1\" is implied, given its relationship to \"phakomatosis\" in some contexts. The presence of a \"Schwannoma\" is my primary concern.\n\n\n**Defining the Most Specific Diagnosis**\n\nI'm now zeroing in on the most precise diagnosis, considering the context of \"Schwannoma\" and the potential implications of \"phakomatosis.\" Given that \"tumor of cranial and spinal nerves\" maps to Schwannoma in the NCI Thesaurus, and the task is to be specific, I am ruling out \"Neurofibromatosis type 1\" as it is less likely than other options, and I am leaning towards \"NF2-related schwannomatosis\" or \"Schwannomatosis\" as the most suitable diagnoses for a Schwannoma patient.\n\n\n**Choosing the Diagnosis**\n\nI'm now focusing on deciding between \"Schwannomatosis\" and \"NF2-related schwannomatosis.\" My analysis indicates that given the \"Schwannoma\" tumor, \"NF2-related schwannomatosis\" might be the best diagnosis, as I am trying to narrow the \"phakomatosis\" category. I am still keeping an open mind about the implications of the \"phakomatosis,\" but the tumor type is swaying the final answer towards a more definitive diagnosis.\n\n\n**Determining Final Mappings**\n\nI've narrowed the diagnosis to either \"NF2-related schwannomatosis\" or \"Schwannomatosis\" given the \"Schwannoma\" tumor type and the broad term \"phakomatosis.\" I'm also confirming the \"cell viability assay\" as the preferred assay, and the tumor mapping to \"Schwannoma.\" Reviewing all mappings together, I now have a solid basis for the most precise and consistent metadata corrections.\n\n\n**Confirming Final Diagnosis**\n\nI'm now determining the most accurate diagnosis, weighing the historical context of \"phakomatosis\" with the \"Schwannoma\" tumor type. I've ruled out NF1 due to the presence of Schwannoma, and I'm currently leaning toward \"NF2-related schwannomatosis,\" though I'm still considering \"Schwannomatosis\" as a potentially safer option. I'm focusing on \"phakomatosis,\" and checking if it's implicitly intended for NF1, even though the tumor field isn't. I'm also confirming a mapping.\n\n\n**Narrowing Diagnosis Further**\n\nI'm now evaluating whether the \"phakomatosis\" might still imply NF1, even with the presence of a Schwannoma. While I previously considered NF2-related schwannomatosis or Schwannomatosis, I am checking the likelihood of this particular scenario, and its prevalence. The instruction to narrow the synonyms is key, and I am now considering if \"Schwannomatosis\" may be broad, and potentially incorrect, and reviewing the specifics of NF1 associated Schwannoma cases, and if they may apply here.\n\n**Narrowing the Focus**\n\nI'm now revisiting the \"phakomatosis\" indication, specifically focusing on its relationship to Neurofibromatosis type 1 (NF1). I'm carefully evaluating the presence of Schwannoma, as this is the key to differentiating between NF1, NF2, and schwannomatosis. My goal is to determine the most specific diagnosis given the existing information and instructions, which indicates a slight favoring of NF1, although the tumor type suggests otherwise.\n\n\n**Determining Specificity**\n\nI'm now determining specificity, now that I've refined the assay to \"cell viability assay\" and the tumor type to \"Schwannoma\". I'm reevaluating the diagnosis \"phakomatosis,\" considering its relationship to both \"Neurofibromatosis type 1\" (NF1) and \"NF2-related schwannomatosis.\" While the tumor type strongly suggests \"NF2-related schwannomatosis,\" the broader term \"phakomatosis\" might imply NF1. The tumor being a Schwannoma is the key detail here, and I'm carefully weighing its implications.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2566,
              "completion_tokens": 4095,
              "total_tokens": 6661,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 4095,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "3D microtissue viability",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2566,
          "output_tokens": 4095,
          "total_tokens": 6661
        },
        "tool_calls": [],
        "tool_execution_history": []
      }
    ],
    "metrics": {
      "total_samples": 10,
      "successful_runs": 10,
      "failed_runs": 0,
      "success_rate": 1.0,
      "average_score": 0.13333333333333333,
      "min_score": 0.0,
      "max_score": 0.6666666666666666,
      "num_scored": 10
    },
    "duration_seconds": 345.0249800682068,
    "token_usage": {
      "input_tokens": 25615,
      "output_tokens": 40060,
      "total_tokens": 65675
    }
  }
}